{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:44:06Z","timestamp":1791297846590,"version":"4.1.0"},"reference-count":620,"publisher":"The Endocrine Society","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2004,6,1]]},"DOI":"10.1210\/er.2003-0014","type":"journal-article","created":{"date-parts":[[2004,6,4]],"date-time":"2004-06-04T21:28:19Z","timestamp":1086384499000},"page":"458-511","source":"Crossref","is-referenced-by-count":495,"title":["The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors"],"prefix":"10.1210","volume":"25","author":[{"given":"Gregory A.","family":"Kaltsas","sequence":"first","affiliation":[{"name":"Department of Endocrinology, St. Bartholomew\u2019s Hospital, London EC1A 7BE, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Michael","family":"Besser","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St. Bartholomew\u2019s Hospital, London EC1A 7BE, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley B.","family":"Grossman","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, St. Bartholomew\u2019s Hospital, London EC1A 7BE, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2016,10,31]]},"reference":[{"key":"2019041122111949200_R1","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/14737159.1.3.323","article-title":"Endocrine tumors of the digestive tract and pancreas: histogenesis, diagnosis and molecular basis.","volume":"1","author":"Rindi","year":"2001","journal-title":"Expert Rev Mol Diagn"},{"key":"2019041122111949200_R2","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1093\/annonc\/10.suppl_2.S9","article-title":"Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract.","volume":"10(Suppl 2)","author":"Solcia","year":"1999","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R3","author":"Solcia","year":"2000"},{"key":"2019041122111949200_R4","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000051851","article-title":"Biological and molecular aspects of gastroenteropancreatic neuroendocrine tumors.","volume":"62(Suppl 1)","author":"Rindi","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R5","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00001622-200201000-00008","article-title":"Carcinoid tumors: molecular genetics, tumor biology, and update of diagnosis and treatment.","volume":"14","author":"Oberg","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"2019041122111949200_R6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1006\/frne.2001.0218","article-title":"Neuroendocrine tumor markers.","volume":"22","author":"Lamberts","year":"2001","journal-title":"Front Neuroendocrinol"},{"key":"2019041122111949200_R7","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1093\/annonc\/12.suppl_2.S47","article-title":"The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours.","volume":"12(Suppl 2)","author":"Kaltsas","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R8","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000051850","article-title":"Molecular genetics of neuroendocrine tumors.","volume":"62(Suppl 1)","author":"Calender","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R9","first-page":"21","article-title":"Neuroendocrine tumors of the lung. Pathology and molecular biology.","volume":"7","author":"Vuitch","year":"1997","journal-title":"Chest Surg Clin N Am"},{"key":"2019041122111949200_R10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000051857","article-title":"Interventional treatment of gastrointestinal neuroendocrine tumours.","volume":"62(Suppl 1)","author":"Ahlman","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0950-3528(96)90013-5","article-title":"Gastrointestinal endocrine tumours. Pathology.","volume":"10","author":"Bishop","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2019041122111949200_R12","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1126\/science.6635661","article-title":"Specific endocrine tissue marker defined by a monoclonal antibody.","volume":"222","author":"Lloyd","year":"1983","journal-title":"Science"},{"key":"2019041122111949200_R13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2559.1985.tb02431.x","article-title":"PGP 9.5, a new marker for human neuroendocrine tumours.","volume":"9","author":"Rode","year":"1985","journal-title":"Histopathology"},{"key":"2019041122111949200_R14","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1073\/pnas.83.10.3500","article-title":"Synaptophysin: a marker protein for neuroendocrine cells and neoplasms.","volume":"83","author":"Wiedenmann","year":"1986","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122111949200_R15","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/BF00199342","article-title":"Revised classification of neuroendocrine tumours of the lung, pancreas and gut.","volume":"425","author":"Capella","year":"1995","journal-title":"Virchows Arch"},{"key":"2019041122111949200_R16","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S0046-8177(98)90070-3","article-title":"Prognostic markers in pheochromocytoma.","volume":"29","author":"Clarke","year":"1998","journal-title":"Hum Pathol"},{"key":"2019041122111949200_R17","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1038\/sj.bjc.6601453","article-title":"The Ki67 index a prognostic marker in medullary thyroid carcinoma.","volume":"89","author":"Tisell","year":"2003","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s002689900021","article-title":"Pathology and nomenclature of human gastrointestinal neuroendocrine (carcinoid) tumors and related lesions.","volume":"20","author":"Kloppel","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R19","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/12.suppl_2.S3","article-title":"Deregulation of genetic pathways in neuroendocrine tumors.","volume":"12(Suppl 2)","author":"Calender","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R20","doi-asserted-by":"crossref","first-page":"5658","DOI":"10.1210\/jcem.86.12.8070","article-title":"Guidelines for diagnosis and therapy of MEN type 1 and type 2.","volume":"86","author":"Brandi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R21","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1053\/snep.2002.30207","article-title":"How many pathways to pheochromocytoma?","volume":"22","author":"Neumann","year":"2002","journal-title":"Semin Nephrol"},{"key":"2019041122111949200_R22","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1056\/NEJM199311183292103","article-title":"Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease.","volume":"329","author":"Neumann","year":"1993","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R23","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"key":"2019041122111949200_R24","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1001\/archsurg.1991.01410320017001","article-title":"The natural history of multiple endocrine neoplasia type 1. Highly uncommon or highly unrecognized?","volume":"126","author":"Shepherd","year":"1991","journal-title":"Arch Surg"},{"key":"2019041122111949200_R25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/ng0897-375","article-title":"Somatic mutation of the MEN1 gene in parathyroid tumours.","volume":"16","author":"Heppner","year":"1997","journal-title":"Nat Genet"},{"key":"2019041122111949200_R26","first-page":"4682","article-title":"Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas.","volume":"57","author":"Zhuang","year":"1997","journal-title":"Cancer Res"},{"key":"2019041122111949200_R27","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1093\/hmg\/6.13.2285","article-title":"Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung.","volume":"6","author":"Debelenko","year":"1997","journal-title":"Hum Mol Genet"},{"key":"2019041122111949200_R28","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1093\/hmg\/11.20.2347","article-title":"The pressure rises: update on the genetics of phaeochromocytoma.","volume":"11","author":"Maher","year":"2002","journal-title":"Hum Mol Genet"},{"key":"2019041122111949200_R29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000061052","article-title":"von Hippel-Lindau disease: genetic and clinical observations.","volume":"28","author":"Iliopoulos","year":"2001","journal-title":"Front Horm Res"},{"key":"2019041122111949200_R30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00005792-198507000-00007","article-title":"The complex of myxomas, spotty pigmentation, and endocrine overactivity.","volume":"64","author":"Carney","year":"1985","journal-title":"Medicine (Baltimore)"},{"key":"2019041122111949200_R31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1172\/JCI118467","article-title":"Carney complex, a familial multiple neoplasia and lentiginosis syndrome. Analysis of 11 kindreds and linkage to the short arm of chromosome 2.","volume":"97","author":"Stratakis","year":"1996","journal-title":"J Clin Invest"},{"key":"2019041122111949200_R32","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jama.1997.03550010065042","article-title":"The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2.","volume":"278","author":"Gutmann","year":"1997","journal-title":"JAMA"},{"key":"2019041122111949200_R33","first-page":"769","article-title":"Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex: two distinctive neuroendocrine syndromes.","volume":"64","author":"Griffiths","year":"1987","journal-title":"Q J Med"},{"key":"2019041122111949200_R34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2265.1999.00756.x","article-title":"Apoptosis in neuroendocrine tumours.","volume":"51","author":"Wang","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R35","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/348334a0","article-title":"Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death.","volume":"348","author":"Hockenbery","year":"1990","journal-title":"Nature"},{"key":"2019041122111949200_R36","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1677\/erc.0.0080307","article-title":"Oncogenic co-operation in \u03b2-cell tumorigenesis.","volume":"8","author":"Pelengaris","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"2019041122111949200_R37","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0092-8674(92)90123-T","article-title":"Induction of apoptosis in fibroblasts by c-myc protein.","volume":"69","author":"Evan","year":"1992","journal-title":"Cell"},{"key":"2019041122111949200_R38","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1046\/j.1365-2559.1998.00321.x","article-title":"Expression of vascular endothelial growth factor in digestive neuroendocrine tumours.","volume":"32","author":"Terris","year":"1998","journal-title":"Histopathology"},{"key":"2019041122111949200_R39","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000051853","article-title":"Tumor markers in neuroendocrine tumors.","volume":"62(Suppl 1)","author":"Eriksson","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R40","first-page":"2622","article-title":"Chromogranin A as serum marker for neuroendocrine neoplasia: comparison with neuron-specific enolase and the \u03b1-subunit of glycoprotein hormones.","volume":"82","author":"Nobels","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R41","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0167-0115(95)00069-N","article-title":"Chromogranin A: current status as a precursor for bioactive peptides and a granulogenic\/sorting factor in the regulated secretory pathway.","volume":"58","author":"Iacangelo","year":"1995","journal-title":"Regul Pept"},{"key":"2019041122111949200_R42","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1056\/NEJMra021405","article-title":"The chromogranin-secretogranin family.","volume":"348","author":"Taupenot","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R43","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1093\/annonc\/12.suppl_2.S79","article-title":"Impact of chromogranin A measurement in the work-up of neuroendocrine tumors.","volume":"12(Suppl 2)","author":"Baudin","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R44","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1056\/NEJM198605013141803","article-title":"Secretion of chromogranin A by peptide-producing endocrine neoplasms.","volume":"314","author":"O\u2019Connor","year":"1986","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/00005792-199101000-00003","article-title":"Chromogranin A storage and secretion: sensitivity and specificity for the diagnosis of pheochromocytoma.","volume":"70","author":"Hsiao","year":"1991","journal-title":"Medicine (Baltimore)"},{"key":"2019041122111949200_R46","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1038\/bjc.1998.635","article-title":"Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours.","volume":"78","author":"Baudin","year":"1998","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R47","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1023\/A:1008215730767","article-title":"Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center.","volume":"8","author":"Janson","year":"1997","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R48","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1507\/endocrj.44.319","article-title":"Plasma chromogranin A in pheochromocytoma, primary hyperparathyroidism and pituitary adenoma in comparison with catecholamine, parathyroid hormone and pituitary hormones.","volume":"44","author":"Kimura","year":"1997","journal-title":"Endocr J"},{"key":"2019041122111949200_R49","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/sj.bjc.6690745","article-title":"Chromogranin A, a significant prognostic factor in small cell lung cancer.","volume":"81","author":"Drivsholm","year":"1999","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R50","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1046\/j.1365-2362.1998.00305.x","article-title":"Chromogranin A: its clinical value as marker of neuroendocrine tumours.","volume":"28","author":"Nobels","year":"1998","journal-title":"Eur J Clin Invest"},{"key":"2019041122111949200_R51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1677\/joe.0.1770337","article-title":"A comparison between three commercial kits for chromogranin A measurements.","volume":"177","author":"Stridsberg","year":"2003","journal-title":"J Endocrinol"},{"key":"2019041122111949200_R52","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0140-6736(98)02286-7","article-title":"Carcinoid tumour.","volume":"352","author":"Caplin","year":"1998","journal-title":"Lancet"},{"key":"2019041122111949200_R53","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/BF00181765","article-title":"Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.","volume":"20","author":"Krenning","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R54","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0001-2998(95)80016-6","article-title":"Therapy of neuroendocrine tumors with radiolabeled MIBG and somatostatin analogues.","volume":"25","author":"Wiseman","year":"1995","journal-title":"Semin Nucl Med"},{"key":"2019041122111949200_R55","first-page":"344","article-title":"Nuclear medicine therapy of pheochromocytoma and paraganglioma.","volume":"43","author":"Troncone","year":"1999","journal-title":"Q J Nucl Med"},{"key":"2019041122111949200_R56","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/j.1749-6632.2002.tb04412.x","article-title":"Radiopharmaceutical treatment of pheochromocytomas.","volume":"970","author":"Sisson","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"2019041122111949200_R57","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000051852","article-title":"Somatostatin receptors.","volume":"62(Suppl 1)","author":"Benali","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R58","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/12.suppl_2.S31","article-title":"Somatostatin receptor subtype expression in human tumors.","volume":"12(Suppl 2)","author":"Hofland","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R59","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000051861","article-title":"Treatment of neuroendocrine GEP tumours with somatostatin analogues: a review.","volume":"62(Suppl 1)","author":"Arnold","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R60","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s002689900031","article-title":"Medical treatment of metastasizing carcinoid tumors.","volume":"20","author":"Arnold","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R61","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1007\/BF01655110","article-title":"Use of octreotide acetate for control of symptoms in patients with islet cell tumors.","volume":"17","author":"Maton","year":"1993","journal-title":"World J Surg"},{"key":"2019041122111949200_R62","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0026-0495(96)90098-0","article-title":"Somatostatin analogs: future directions.","volume":"45","author":"Lamberts","year":"1996","journal-title":"Metabolism"},{"key":"2019041122111949200_R63","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide.","volume":"334","author":"Lamberts","year":"1996","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R64","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1210\/mend.13.1.0220","article-title":"C-terminal region of human somatostatin receptor 5 is required for induction of Rb and G1 cell cycle arrest.","volume":"13","author":"Sharma","year":"1999","journal-title":"Mol Endocrinol"},{"key":"2019041122111949200_R65","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/bjc.1992.65","article-title":"Insulin-like growth factors and cancer.","volume":"65","author":"Macaulay","year":"1992","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R66","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1046\/j.1365-2265.2002.01619.x","article-title":"Antiangiogenic effects of somatostatin analogues.","volume":"57","author":"Garcia de la Torre","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R67","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1749-6632.1994.tb17262.x","article-title":"Expression of somatostatin receptors in normal, inflamed, and neoplastic human gastrointestinal tissues.","volume":"733","author":"Reubi","year":"1994","journal-title":"Ann NY Acad Sci"},{"key":"2019041122111949200_R68","first-page":"1825","article-title":"Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.","volume":"36","author":"Reubi","year":"1995","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R69","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1136\/pgmj.72.849.403","article-title":"Somatostatin analogue treatment of neuroendocrine tumours.","volume":"72","author":"Herder","year":"1996","journal-title":"Postgrad Med J"},{"key":"2019041122111949200_R70","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0001-2998(95)80014-X","article-title":"Somatostatin receptor imaging of neuroendocrine tumors with indium-111 pentetreotide (Octreoscan).","volume":"25","author":"Olsen","year":"1995","journal-title":"Semin Nucl Med"},{"key":"2019041122111949200_R71","first-page":"2375","article-title":"Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies.","volume":"58","author":"Janson","year":"1998","journal-title":"Cancer Res"},{"key":"2019041122111949200_R72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/BF00173045","article-title":"Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.","volume":"21","author":"Hoefnagel","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R73","first-page":"1704","article-title":"Peptide receptor imaging and therapy.","volume":"41","author":"Kwekkeboom","year":"2000","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R74","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00001622-200201000-00010","article-title":"Somatostatin and somatostatin analogues: diagnostic and therapeutic uses.","volume":"14","author":"Herder","year":"2002","journal-title":"Curr Opin Oncol"},{"key":"2019041122111949200_R75","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1210\/edrv-12-4-450","article-title":"The role of somatostatin and its analogs in the diagnosis and treatment of tumors.","volume":"12","author":"Lamberts","year":"1991","journal-title":"Endocr Rev"},{"key":"2019041122111949200_R76","first-page":"150","article-title":"Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.","volume":"39","author":"Shapiro","year":"1995","journal-title":"Q J Nucl Med"},{"key":"2019041122111949200_R77","first-page":"3","article-title":"The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.","volume":"39","author":"Shapiro","year":"1995","journal-title":"Q J Nucl Med"},{"key":"2019041122111949200_R78","first-page":"197","article-title":"[Radioisotopic imaging of neuroendocrine tumours. Which radiopharmaceutical and which diagnostic procedure?].","volume":"26","author":"Bombardieri","year":"2001","journal-title":"Minerva Endocrinol"},{"key":"2019041122111949200_R79","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1046\/j.1365-2265.2001.01309.x","article-title":"Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].","volume":"55","author":"Mukherjee","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R80","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1007\/s002680010213","article-title":"Nuclear medicine applications for neuroendocrine tumors.","volume":"24","author":"Chatal","year":"2000","journal-title":"World J Surg"},{"key":"2019041122111949200_R81","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1023\/A:1026592025862","article-title":"Improved effect of 131I-MIBG treatment by predosing with non-radiolabeled MIBG in carcinoid patients, and studies in xenografted mice.","volume":"11","author":"Taal","year":"2000","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R82","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","article-title":"Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin.","volume":"1","author":"Krenning","year":"1989","journal-title":"Lancet"},{"key":"2019041122111949200_R83","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","article-title":"Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.","volume":"10(Suppl 2)","author":"Krenning","year":"1999","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R84","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(05)78355-0","article-title":"Yttrium-90-labelled somatostatin-analogue for cancer treatment.","volume":"351","author":"Otte","year":"1998","journal-title":"Lancet"},{"key":"2019041122111949200_R85","first-page":"623","article-title":"Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.","volume":"36","author":"Breeman","year":"1995","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R86","first-page":"1134","article-title":"Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.","volume":"42","author":"Balon","year":"2001","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R87","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/BF00209003","article-title":"Improved visualization of carcinoid liver metastases by indium-111 pentetreotide scintigraphy following treatment with cold somatostatin analogue.","volume":"20","author":"Dorr","year":"1993","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R88","first-page":"6","article-title":"Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.","volume":"21","author":"Krenning","year":"1994","journal-title":"Semin Oncol"},{"key":"2019041122111949200_R89","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1749-6632.1994.tb17291.x","article-title":"Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors. An overview of European results.","volume":"733","author":"Krenning","year":"1994","journal-title":"Ann NY Acad Sci"},{"key":"2019041122111949200_R90","first-page":"88","article-title":"Octreotide agent shows peptide imaging potential.","volume":"15","author":"Krenning","year":"1993","journal-title":"Diagn Imaging (San Franc)"},{"key":"2019041122111949200_R91","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000201083","article-title":"111In-octreotide scintigraphy in oncology.","volume":"54(Suppl 1)","author":"Krenning","year":"1993","journal-title":"Digestion"},{"key":"2019041122111949200_R92","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1007\/s002590050314","article-title":"Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.","volume":"25","author":"Chiti","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R93","doi-asserted-by":"crossref","first-page":"26","DOI":"10.7326\/0003-4819-125-1-199607010-00005","article-title":"Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study.","volume":"125","author":"Gibril","year":"1996","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R94","first-page":"539","article-title":"Specificity of somatostatin receptor scintigraphy: a prospective study and effects of false-positive localizations on management in patients with gastrinomas.","volume":"40","author":"Gibril","year":"1999","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R95","first-page":"17","author":"Kwekkeboom","year":"2002"},{"key":"2019041122111949200_R96","doi-asserted-by":"crossref","first-page":"3698","DOI":"10.1210\/endo.136.9.7649075","article-title":"Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide.","volume":"136","author":"Hofland","year":"1995","journal-title":"Endocrinology"},{"key":"2019041122111949200_R97","first-page":"308","article-title":"[131I]metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication.","volume":"35","author":"Hoefnagel","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R98","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1046\/j.1365-2265.1998.00527.x","article-title":"Carcinoid tumours presenting as breast cancer: the utility of radionuclide imaging with 123I-MIBG and 111In-DTPA pentetreotide.","volume":"49","author":"Kaltsas","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R99","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1210\/jcem.86.2.7194","article-title":"Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors.","volume":"86","author":"Kaltsas","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R100","first-page":"213","article-title":"64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.","volume":"42","author":"Anderson","year":"2001","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R101","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM199410273311703","article-title":"Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.","volume":"331","author":"Virgolini","year":"1994","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R102","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/bip.10347","article-title":"Radiolabeling approaches for cholecystokinin B receptor imaging.","volume":"66","author":"Aloj","year":"2002","journal-title":"Biopolymers"},{"key":"2019041122111949200_R103","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00259-002-1107-8","article-title":"Radiolabelled peptides for tumour therapy: current status and future directions. Plenary lecture at the EANM 2002.","volume":"30","author":"Jong","year":"2003","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2019041122111949200_R104","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1749-6632.2002.tb04422.x","article-title":"The role of PET in localization of neuroendocrine and adrenocortical tumors.","volume":"970","author":"Eriksson","year":"2002","journal-title":"Ann NY Acad Sci"},{"key":"2019041122111949200_R105","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.2214\/ajr.170.5.9574618","article-title":"Evaluation of primary pulmonary carcinoid tumors using FDG PET.","volume":"170","author":"Erasmus","year":"1998","journal-title":"AJR Am J Roentgenol"},{"key":"2019041122111949200_R106","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s002590050197","article-title":"Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours.","volume":"25","author":"Adams","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R107","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1200\/JCO.1998.16.7.2534","article-title":"Positron emission tomography with 5-hydroxytryprophan in neuroendocrine tumors.","volume":"16","author":"Orlefors","year":"1998","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R108","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0969-8051(99)00085-2","article-title":"Demonstration of [11C] 5-hydroxy-L-tryptophan uptake and decarboxylation in carcinoid tumors by specific positioning labeling in positron emission tomography.","volume":"27","author":"Sundin","year":"2000","journal-title":"Nucl Med Biol"},{"key":"2019041122111949200_R109","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000051856","article-title":"Natural history of neuroendocrine enteropancreatic tumors.","volume":"62(Suppl 1)","author":"Mignon","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R110","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/thy.1995.5.407","article-title":"Medullary thyroid carcinoma: recent advances and management update.","volume":"5","author":"Marsh","year":"1995","journal-title":"Thyroid"},{"key":"2019041122111949200_R111","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1097\/00045415-200201000-00009","article-title":"Pheochromocytoma.","volume":"10","author":"Bravo","year":"2002","journal-title":"Cardiol Rev"},{"key":"2019041122111949200_R112","first-page":"31","author":"Rindi","year":"2002"},{"key":"2019041122111949200_R113","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00268-001-0017-4","article-title":"Nonsurgical treatment of advanced malignant neuroendocrine pancreatic tumors and midgut carcinoids.","volume":"25","author":"Skogseid","year":"2001","journal-title":"World J Surg"},{"key":"2019041122111949200_R114","doi-asserted-by":"crossref","first-page":"267","DOI":"10.7326\/0003-4819-109-4-267","article-title":"Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.","volume":"109","author":"Averbuch","year":"1988","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R115","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1210\/edrv-15-3-356","article-title":"Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma.","volume":"15","author":"Bravo","year":"1994","journal-title":"Endocr Rev"},{"key":"2019041122111949200_R116","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2265.2001.01396.x","article-title":"The role of chemotherapy in the nonsurgical management of malignant neuroendocrine tumours.","volume":"55","author":"Kaltsas","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R117","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1200\/JCO.1997.15.6.2420","article-title":"Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns.","volume":"15","author":"Sutliff","year":"1997","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R118","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0960-7404(01)00007-X","article-title":"Recent advances in carcinoid pathogenesis, diagnosis and management.","volume":"9","author":"Ganim","year":"2000","journal-title":"Surg Oncol"},{"key":"2019041122111949200_R119","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1056\/NEJM199903183401107","article-title":"Carcinoid tumors.","volume":"340","author":"Kulke","year":"1999","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R120","doi-asserted-by":"crossref","first-page":"209","DOI":"10.7326\/0003-4819-117-3-209","article-title":"The Cushing syndrome induced by bronchial carcinoid tumors.","volume":"117","author":"Limper","year":"1992","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R121","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S0889-8553(21)00446-5","article-title":"Clinical features, diagnosis, and localization of carcinoid tumors and their management.","volume":"18","author":"Vinik","year":"1989","journal-title":"Gastroenterol Clin North Am"},{"key":"2019041122111949200_R122","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00001622-200007000-00015","article-title":"Carcinoid and pancreatic endocrine tumors: recent advances in molecular pathogenesis, localization, and treatment.","volume":"12","author":"Jensen","year":"2000","journal-title":"Curr Opin Oncol"},{"key":"2019041122111949200_R123","doi-asserted-by":"crossref","first-page":"5166","DOI":"10.1073\/pnas.93.10.5166","article-title":"Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.","volume":"93","author":"Erickson","year":"1996","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122111949200_R124","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1093\/annonc\/12.suppl_2.S63","article-title":"The gut as the largest endocrine organ in the body.","volume":"12(Suppl 2)","author":"Ahlman","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R125","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/bjc.1994.424","article-title":"The epidemiology of carcinoid tumours in England and Scotland.","volume":"70","author":"Newton","year":"1994","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R126","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2","article-title":"An analysis of 8305 cases of carcinoid tumors.","volume":"79","author":"Modlin","year":"1997","journal-title":"Cancer"},{"key":"2019041122111949200_R127","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1053\/gast.1997.v112.pm9024313","article-title":"Approaches to the diagnosis of gut neuroendocrine tumors: the last word (today).","volume":"112","author":"Modlin","year":"1997","journal-title":"Gastroenterology"},{"key":"2019041122111949200_R128","first-page":"322","article-title":"Carcinoid tumours. Frequency in a defined population during a 12-year period.","volume":"84","author":"Berge","year":"1976","journal-title":"Acta Pathol Microbiol Scand [A]"},{"key":"2019041122111949200_R129","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1002\/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R","article-title":"Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden.","volume":"92","author":"Hemminki","year":"2001","journal-title":"Cancer"},{"key":"2019041122111949200_R130","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1023\/A:1012272314550","article-title":"Epidemiology and survival in patients with carcinoid disease in The Netherlands. An epidemiological study with 2391 patients.","volume":"12","author":"Quaedvlieg","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R131","first-page":"389","article-title":"Carcinoid tumour.","volume":"93","author":"McStay","year":"2002","journal-title":"Minerva Med"},{"key":"2019041122111949200_R132","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/pgmj.73.858.207","article-title":"Carcinoid tumours.","volume":"73","author":"Janmohamed","year":"1997","journal-title":"Postgrad Med J"},{"key":"2019041122111949200_R133","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/0002-9610(87)90305-9","article-title":"Carcinoids associated with multiple endocrine neoplasia syndromes.","volume":"154","author":"Duh","year":"1987","journal-title":"Am J Surg"},{"key":"2019041122111949200_R134","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1002\/1097-0142(19830615)51:12<2206::AID-CNCR2820511209>3.0.CO;2-B","article-title":"Von Recklinghausen\u2019s disease associated with gastrointestinal carcinoid tumors.","volume":"51","author":"Hough","year":"1983","journal-title":"Cancer"},{"key":"2019041122111949200_R135","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/1097-0142(19890115)63:2<390::AID-CNCR2820630232>3.0.CO;2-K","article-title":"Can susceptibility to carcinoid tumors be inherited?","volume":"63","author":"Yeatman","year":"1989","journal-title":"Cancer"},{"key":"2019041122111949200_R136","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ijc.1473","article-title":"Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden.","volume":"94","author":"Hemminki","year":"2001","journal-title":"Int J Cancer"},{"key":"2019041122111949200_R137","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1097\/00000658-200010000-00010","article-title":"Gastrointestinal carcinoids: characterization by site of origin and hormone production.","volume":"232","author":"Onaitis","year":"2000","journal-title":"Ann Surg"},{"key":"2019041122111949200_R138","first-page":"133","article-title":"Carcinoid syndrome: a statistical evaluation of 748 reported cases.","volume":"18","author":"Soga","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"key":"2019041122111949200_R139","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/annonc\/12.suppl_2.S95","article-title":"Epidemiology, clinical features and diagnosis of gastroenteropancreatic endocrine tumours.","volume":"12(Suppl 2)","author":"Tomassetti","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R140","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/0003-4975(92)91139-Z","article-title":"Bronchial carcinoid tumors: a retrospective analysis of 126 patients.","volume":"54","author":"Harpole Jr","year":"1992","journal-title":"Ann Thorac Surg"},{"key":"2019041122111949200_R141","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0003-4975(94)00630-P","article-title":"Carcinoid tumors of the lung: do atypical features require aggressive management?","volume":"59","author":"Marty-Ane","year":"1995","journal-title":"Ann Thorac Surg"},{"key":"2019041122111949200_R142","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0022-5223(19)38687-8","article-title":"Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants.","volume":"89","author":"Warren","year":"1985","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2019041122111949200_R143","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/00000478-199808000-00003","article-title":"Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid.","volume":"22","author":"Travis","year":"1998","journal-title":"Am J Surg Pathol"},{"key":"2019041122111949200_R144","first-page":"3425","article-title":"Prognostic markers in patients with typical bronchial carcinoid tumors.","volume":"85","author":"Granberg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R145","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1378\/chest.119.6.1647","article-title":"Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature.","volume":"119","author":"Fink","year":"2001","journal-title":"Chest"},{"key":"2019041122111949200_R146","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0950-3528(96)90015-9","article-title":"Carcinoid tumours.","volume":"10","author":"Tiensuu Janson","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2019041122111949200_R147","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0954-6111(89)80201-X","article-title":"Typical and atypical bronchial carcinoids.","volume":"83","author":"Torre","year":"1989","journal-title":"Respir Med"},{"key":"2019041122111949200_R148","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1016\/S0022-5223(19)34645-8","article-title":"A twenty-five-year follow-up of ninety-three resected typical carcinoid tumors of the lung.","volume":"104","author":"Schreurs","year":"1992","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2019041122111949200_R149","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s002689900029","article-title":"Pulmonary and thymic carcinoid tumors.","volume":"20","author":"Dusmet","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R150","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1245\/ASO.2003.09.019","article-title":"Update in pulmonary carcinoid tumors: a review article.","volume":"10","author":"Hage","year":"2003","journal-title":"Ann Surg Oncol"},{"key":"2019041122111949200_R151","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1046\/j.1365-2796.1998.00329.x","article-title":"Thymic carcinoids in multiple endocrine neoplasia type 1.","volume":"243","author":"Teh","year":"1998","journal-title":"J Intern Med"},{"key":"2019041122111949200_R152","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/00005792-199701000-00002","article-title":"Clinicopathologic studies of thymic carcinoids in multiple endocrine neoplasia type 1.","volume":"76","author":"Teh","year":"1997","journal-title":"Medicine (Baltimore)"},{"key":"2019041122111949200_R153","first-page":"285","article-title":"Evaluation of 342 cases of mediastinal\/thymic carcinoids collected from literature: a comparative study between typical carcinoids and atypical varieties.","volume":"5","author":"Soga","year":"1999","journal-title":"Ann Thorac Cardiovasc Surg"},{"key":"2019041122111949200_R154","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1309\/3PDN-PMT5-EQTM-H0CD","article-title":"Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathologic analysis of 80 cases.","volume":"114","author":"Moran","year":"2000","journal-title":"Am J Clin Pathol"},{"key":"2019041122111949200_R155","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1210\/jc.2002-021314","article-title":"Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1.","volume":"88","author":"Gibril","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R156","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s002689900026","article-title":"Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior.","volume":"20","author":"Rindi","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R157","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/BF02388135","article-title":"Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature.","volume":"27","author":"Soga","year":"1997","journal-title":"Surg Today"},{"key":"2019041122111949200_R158","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/BF00353739","article-title":"Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia.","volume":"18","author":"Gough","year":"1994","journal-title":"World J Surg"},{"key":"2019041122111949200_R159","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/0016-5085(93)90266-F","article-title":"Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study.","volume":"104","author":"Rindi","year":"1993","journal-title":"Gastroenterology"},{"key":"2019041122111949200_R160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s002689900027","article-title":"Management of carcinoid tumors of the stomach, duodenum, and pancreas.","volume":"20","author":"Akerstrom","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R161","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1136\/gut.43.2.223","article-title":"Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids.","volume":"43","author":"Granberg","year":"1998","journal-title":"Gut"},{"key":"2019041122111949200_R162","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0950-3528(96)90016-0","article-title":"Gastrointestinal endocrine tumours. Gastrinoma.","volume":"10","author":"Jensen","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2019041122111949200_R163","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0016-5085(99)70174-5","article-title":"ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis.","volume":"116","author":"Rindi","year":"1999","journal-title":"Gastroenterology"},{"key":"2019041122111949200_R164","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0960-7404(03)00034-3","article-title":"Carcinoid tumors of the stomach.","volume":"12","author":"Modlin","year":"2003","journal-title":"Surg Oncol"},{"key":"2019041122111949200_R165","doi-asserted-by":"crossref","first-page":"134","DOI":"10.2302\/kjm.52.134","article-title":"Gastric stem cells: an update.","volume":"52","author":"Modlin","year":"2003","journal-title":"Keio J Med"},{"key":"2019041122111949200_R166","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jamcollsurg.2003.08.018","article-title":"Multiple gastric carcinoids.","volume":"198","author":"Modlin","year":"2004","journal-title":"J Am Coll Surg"},{"key":"2019041122111949200_R167","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1046\/j.1572-0241.2003.04027.x","article-title":"A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem?","volume":"99","author":"Modlin","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2019041122111949200_R168","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1067\/msy.2099.101430","article-title":"Foregut carcinoids: a clinical and biochemical analysis.","volume":"126","author":"Kirshbom","year":"1999","journal-title":"Surgery"},{"key":"2019041122111949200_R169","first-page":"349","article-title":"Endocrinocarcinomas (carcinoids and their variants) of the duodenum. An evaluation of 927 cases.","volume":"22","author":"Soga","year":"2003","journal-title":"J Exp Clin Cancer Res"},{"key":"2019041122111949200_R170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1385\/IJGC:23:2:153","article-title":"Carcinoid tumors of the pancreas. Status report based on two cases and review of the world\u2019s literature.","volume":"23","author":"Mao","year":"1998","journal-title":"Int J Pancreatol"},{"key":"2019041122111949200_R171","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/0959-8049(96)00049-4","article-title":"Carcinoid of the pancreas: clinical characteristics and morphological features.","volume":"32A","author":"Maurer","year":"1996","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R172","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00001622-199801000-00010","article-title":"Advances in chemotherapy and biotherapy of endocrine tumors.","volume":"10","author":"Oberg","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"2019041122111949200_R173","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/(SICI)1097-0142(19970315)79:6<1086::AID-CNCR5>3.0.CO;2-E","article-title":"Carcinoids of the jejunum and ileum: an immunohistochemical and clinicopathologic study of 167 cases.","volume":"79","author":"Burke","year":"1997","journal-title":"Cancer"},{"key":"2019041122111949200_R174","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/BF01658532","article-title":"Surgical treatment of mid-gut carcinoid tumors.","volume":"14","author":"Makridis","year":"1990","journal-title":"World J Surg"},{"key":"2019041122111949200_R175","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/02841869309083916","article-title":"Long-term management of the carcinoid syndrome. Treatment with octreotide alone and in combination with \u03b1-interferon.","volume":"32","author":"Janson","year":"1993","journal-title":"Acta Oncol"},{"key":"2019041122111949200_R176","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/cncr.11105","article-title":"A 5-decade analysis of 13,715 carcinoid tumors.","volume":"97","author":"Modlin","year":"2003","journal-title":"Cancer"},{"key":"2019041122111949200_R177","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1067\/msy.1998.93105","article-title":"Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids.","volume":"124","author":"Kirshbom","year":"1998","journal-title":"Surgery"},{"key":"2019041122111949200_R178","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s002689900387","article-title":"Preoperative diagnosis and surgical management of neuroendocrine gastroenteropancreatic tumors: general recommendations by a consensus workshop.","volume":"22","author":"Wiedenmann","year":"1998","journal-title":"World J Surg"},{"key":"2019041122111949200_R179","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/path.1711620303","article-title":"Carcinoid tumours of the appendix are different.","volume":"162","author":"Shaw","year":"1990","journal-title":"J Pathol"},{"key":"2019041122111949200_R180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/00000658-199304000-00010","article-title":"Carcinoid tumors of the appendix.","volume":"217","author":"Roggo","year":"1993","journal-title":"Ann Surg"},{"key":"2019041122111949200_R181","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJM198712313172704","article-title":"Carcinoid tumor of the appendix: treatment and prognosis.","volume":"317","author":"Moertel","year":"1987","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R182","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1200\/JCO.1987.5.10.1502","article-title":"Karnofsky memorial lecture. An odyssey in the land of small tumors.","volume":"5","author":"Moertel","year":"1987","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R183","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0002-9610(05)80145-X","article-title":"Goblet cell carcinoid of the appendix.","volume":"168","author":"Butler","year":"1994","journal-title":"Am J Surg"},{"key":"2019041122111949200_R184","doi-asserted-by":"crossref","first-page":"386","DOI":"10.5858\/2001-125-0386-GCCOTA","article-title":"Goblet cell carcinoids of the appendix: immunophenotype and ultrastructural study.","volume":"125","author":"Kanthan","year":"2001","journal-title":"Arch Pathol Lab Med"},{"key":"2019041122111949200_R185","first-page":"139","article-title":"Carcinoids of the colon and ileocecal region: a statistical evaluation of 363 cases collected from the literature.","volume":"17","author":"Soga","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"2019041122111949200_R186","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0002-9610(85)80184-7","article-title":"Carcinoid tumors of the colon. A study of 72 patients.","volume":"149","author":"Rosenberg","year":"1985","journal-title":"Am J Surg"},{"key":"2019041122111949200_R187","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1002\/1097-0142(19920515)69:10<2400::AID-CNCR2820691003>3.0.CO;2-Z","article-title":"Incidence and mortality of carcinoids of the colon. Data from the Connecticut Tumor Registry.","volume":"69","author":"Ballantyne","year":"1992","journal-title":"Cancer"},{"key":"2019041122111949200_R188","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1093\/annonc\/12.suppl_2.S101","article-title":"Surgical strategy in the treatment of gastrointestinal neuroendocrine tumours.","volume":"12(Suppl 2)","author":"Falconi","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R189","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/BF02385898","article-title":"Carcinoids of the rectum: an evaluation of 1271 reported cases.","volume":"27","author":"Soga","year":"1997","journal-title":"Surg Today"},{"key":"2019041122111949200_R190","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/1097-0142(19900101)65:1<135::AID-CNCR2820650127>3.0.CO;2-A","article-title":"Rectal and colonic carcinoids. A clinicopathologic study of 84 cases.","volume":"65","author":"Federspiel","year":"1990","journal-title":"Cancer"},{"key":"2019041122111949200_R191","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/(SICI)1097-0142(19970401)79:7<1294::AID-CNCR4>3.0.CO;2-H","article-title":"Carcinoid tumors of the rectum: effect of size, histopathology, and surgical treatment on metastasis free survival.","volume":"79","author":"Koura","year":"1997","journal-title":"Cancer"},{"key":"2019041122111949200_R192","first-page":"271","article-title":"Carcinoids of the ovary: an analysis of 329 reported cases.","volume":"19","author":"Soga","year":"2000","journal-title":"J Exp Clin Cancer Res"},{"key":"2019041122111949200_R193","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1006\/gyno.1996.0136","article-title":"Primary ovarian carcinoid tumors.","volume":"61","author":"Davis","year":"1996","journal-title":"Gynecol Oncol"},{"key":"2019041122111949200_R194","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1210\/jcem.87.4.8407","article-title":"Ocular metastases secondary to carcinoid tumors: the utility of imaging with [(123)I]meta-iodobenzylguanidine and [(111)In]DTPA pentetreotide.","volume":"87","author":"Isidori","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R195","first-page":"276","article-title":"Carcinoid tumour of the middle ear: case report and review of the literature.","volume":"23","author":"Riddell","year":"1994","journal-title":"J Otolaryngol"},{"key":"2019041122111949200_R196","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/S0735-1097(02)02109-5","article-title":"Metastatic carcinoid tumor to the heart: echocardiographic-pathologic study of 11 patients.","volume":"40","author":"Pandya","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2019041122111949200_R197","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/modpathol.3880561","article-title":"Adenoma versus carcinoid tumor of the middle ear: a study of 48 cases and review of the literature.","volume":"15","author":"Torske","year":"2002","journal-title":"Mod Pathol"},{"key":"2019041122111949200_R198","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF02924009","article-title":"Primary carcinoid tumor of the testis.","volume":"12","author":"Frank","year":"1991","journal-title":"Urol Radiol"},{"key":"2019041122111949200_R199","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0002-9149(99)80586-4","article-title":"Predictors of outcome of tricuspid valve replacement in carcinoid heart disease.","volume":"75","author":"Robiolio","year":"1995","journal-title":"Am J Cardiol"},{"key":"2019041122111949200_R200","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMc030888","article-title":"Carcinoid heart disease.","volume":"348","author":"Horst-Schrivers","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R201","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1161\/01.CIR.92.4.790","article-title":"Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography.","volume":"92","author":"Robiolio","year":"1995","journal-title":"Circulation"},{"key":"2019041122111949200_R202","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1161\/01.CIR.87.4.1188","article-title":"Carcinoid heart disease. Clinical and echocardiographic spectrum in 74 patients.","volume":"87","author":"Pellikka","year":"1993","journal-title":"Circulation"},{"key":"2019041122111949200_R203","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1056\/NEJM199809103391101","article-title":"The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs.","volume":"339","author":"Khan","year":"1998","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R204","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJM199809103391102","article-title":"A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.","volume":"339","author":"Jick","year":"1998","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R205","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMc030888","article-title":"Carcinoid heart disease.","volume":"348","author":"Zuetenhorst","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R206","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/cncr.11226","article-title":"Carcinoid heart disease: the role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-\u03b2 and fibroblast growth factor.","volume":"97","author":"Zuetenhorst","year":"2003","journal-title":"Cancer"},{"key":"2019041122111949200_R207","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1056\/NEJMoa021451","article-title":"Factors associated with progression of carcinoid heart disease.","volume":"348","author":"Moller","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R208","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1046\/j.0007-1323.2001.01798.x","article-title":"Prediction of prognosis by echocardiography in patients with midgut carcinoid syndrome.","volume":"88","author":"Westberg","year":"2001","journal-title":"Br J Surg"},{"key":"2019041122111949200_R209","first-page":"748","article-title":"Expression of platelet-derived growth factor \u03b2-receptors on stromal tissue cells in human carcinoid tumors.","volume":"50","author":"Funa","year":"1990","journal-title":"Cancer Res"},{"key":"2019041122111949200_R210","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(86)90583-8","article-title":"Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors.","volume":"81","author":"Feldman","year":"1986","journal-title":"Am J Med"},{"key":"2019041122111949200_R211","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1210\/jcem-63-3-605","article-title":"Tachykinins in carcinoid tumors: their use as a tumor marker and possible role in the carcinoid flush.","volume":"63","author":"Norheim","year":"1986","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R212","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1515\/CCLM.1998.147","article-title":"Usefulness of chromogranin A as a marker for detection of relapses of carcinoid tumours.","volume":"36","author":"Pirker","year":"1998","journal-title":"Clin Chem Lab Med"},{"key":"2019041122111949200_R213","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/00042737-200101000-00010","article-title":"Diagnostic value of plasma chromogranin A in neuroendocrine tumours.","volume":"13","author":"Tomassetti","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2019041122111949200_R214","first-page":"43","author":"Herder","year":"2002"},{"key":"2019041122111949200_R215","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s002689900023","article-title":"Carcinoid tumors: imaging procedures and interventional radiology.","volume":"20","author":"Wallace","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R216","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/0026-0495(90)90217-Z","article-title":"Distribution of somatostatin receptors in normal and tumor tissue.","volume":"39","author":"Reubi","year":"1990","journal-title":"Metabolism"},{"key":"2019041122111949200_R217","first-page":"1514","article-title":"Nuclear localization of 111In after intravenous injection of [111In-DTPA-D-Phe1]-octreotide in patients with neuroendocrine tumors.","volume":"41","author":"Janson","year":"2000","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R218","first-page":"5801","article-title":"Somatostatin receptor scintigraphy in patients with carcinoid tumors: comparison between radioligand uptake and tumor markers.","volume":"55","author":"Kalkner","year":"1995","journal-title":"Cancer Res"},{"key":"2019041122111949200_R219","doi-asserted-by":"crossref","first-page":"4754","DOI":"10.1210\/jc.2003-030525","article-title":"A reappraisal of the utility of somatostatin receptor scintigraphy in patients with ectopic adrenocorticotropin Cushing\u2019s syndrome.","volume":"88","author":"Tsagarakis","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R220","first-page":"634","article-title":"In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.","volume":"39","author":"Lastoria","year":"1998","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R221","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/bjs.1800770919","article-title":"Primary gastric carcinoids: a view on management.","volume":"77","author":"Davies","year":"1990","journal-title":"Br J Surg"},{"key":"2019041122111949200_R222","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0720-048X(00)00187-X","article-title":"Standardisation of imaging in neuroendocrine tumours: results of a European delphi process.","volume":"37","author":"Ricke","year":"2001","journal-title":"Eur J Radiol"},{"key":"2019041122111949200_R223","first-page":"853","article-title":"Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors.","volume":"38","author":"Lebtahi","year":"1997","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R224","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1053\/gast.1997.v112.pm9024287","article-title":"Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management.","volume":"112","author":"Termanini","year":"1997","journal-title":"Gastroenterology"},{"key":"2019041122111949200_R225","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1136\/gut.41.1.107","article-title":"Usefulness of somatostatin receptor scintigraphy in the management of patients with Zollinger-Ellison syndrome. Groupe de Recherche et d\u2019Etude du Syndrome de Zollinger-Ellison (GRESZE).","volume":"41","author":"Cadiot","year":"1997","journal-title":"Gut"},{"key":"2019041122111949200_R226","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF00199642","article-title":"Sonographic appearance of primary small bowel carcinoid tumor.","volume":"20","author":"Rioux","year":"1995","journal-title":"Abdom Imaging"},{"key":"2019041122111949200_R227","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1097\/00000658-198712000-00007","article-title":"Percutaneous ultrasonography-guided cutting biopsy from liver metastases of endocrine gastrointestinal tumors.","volume":"206","author":"Andersson","year":"1987","journal-title":"Ann Surg"},{"key":"2019041122111949200_R228","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jmri.1880060603","article-title":"Small bowel neoplastic disease: demonstration by MRI.","volume":"6","author":"Semelka","year":"1996","journal-title":"J Magn Reson Imaging"},{"key":"2019041122111949200_R229","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1177\/028418519503600407","article-title":"Midgut carcinoid tumours. CT appearance.","volume":"36","author":"Sugimoto","year":"1995","journal-title":"Acta Radiol"},{"key":"2019041122111949200_R230","first-page":"1054","article-title":"Carcinoid tumors of the gastrointestinal tract: presentation, management, and prognosis.","volume":"98","author":"Thompson","year":"1985","journal-title":"Surgery"},{"key":"2019041122111949200_R231","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0016-5107(95)70196-6","article-title":"Endoscopic assessment of invasion of colorectal tumors with a new high-frequency ultrasound probe.","volume":"41","author":"Yoshida","year":"1995","journal-title":"Gastrointest Endosc"},{"key":"2019041122111949200_R232","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1590-8658(01)80710-6","article-title":"Digestive neuroendocrine tumours: diagnosis and treatment in Italy. A survey by the Oncology Study Section of the Italian Society of Gastroenterology (SIGE).","volume":"33","author":"Corleto","year":"2001","journal-title":"Dig Liver Dis"},{"key":"2019041122111949200_R233","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2265.2003.01885.x","article-title":"SPECT\/CT hybrid imaging with 111In-pentetreotide in assessment of neuroendocrine tumours.","volume":"59","author":"Krausz","year":"2003","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R234","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0889-8529(18)30379-7","article-title":"Treatment of endocrine tumors of the pancreas.","volume":"18","author":"Vinik","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R235","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00001622-199801000-00007","article-title":"Imaging advances in the diagnosis of endocrine neoplasia.","volume":"10","author":"Scott","year":"1998","journal-title":"Curr Opin Oncol"},{"key":"2019041122111949200_R236","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0025-6196(12)62083-7","article-title":"Functioning insulinoma\u2013incidence, recurrence, and long-term survival of patients: a 60-year study.","volume":"66","author":"Service","year":"1991","journal-title":"Mayo Clin Proc"},{"key":"2019041122111949200_R237","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00002142-199610000-00003","article-title":"MR imaging of pancreatic disorders.","volume":"8","author":"Outwater","year":"1996","journal-title":"Top Magn Reson Imaging"},{"key":"2019041122111949200_R238","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0889-8529(05)70086-4","article-title":"Diagnostic approach to adults with hypoglycemic disorders.","volume":"28","author":"Service","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R239","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1146\/annurev.med.47.1.57","article-title":"Endocrine tumors of the gastrointestinal tract.","volume":"47","author":"Perry","year":"1996","journal-title":"Annu Rev Med"},{"key":"2019041122111949200_R240","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S0950-3528(96)90017-2","article-title":"Gastrointestinal endocrine tumours. Insulinoma.","volume":"10","author":"Grant","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2019041122111949200_R241","doi-asserted-by":"crossref","first-page":"824","DOI":"10.12968\/hosp.2000.61.12.1478","article-title":"Islet cell tumours: diagnosis and medical management.","volume":"61","author":"Taheri","year":"2000","journal-title":"Hosp Med"},{"key":"2019041122111949200_R242","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0889-8529(18)30388-8","article-title":"Insulin-producing islet cell tumors.","volume":"18","author":"Fajans","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R243","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199909023411004","article-title":"Hypoglycemia due to an insulin-secreting small-cell carcinoma of the cervix.","volume":"341","author":"Seckl","year":"1999","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R244","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0002-9343(99)00021-2","article-title":"Neuroglycopenic and other symptoms in patients with insulinomas.","volume":"106","author":"Dizon","year":"1999","journal-title":"Am J Med"},{"key":"2019041122111949200_R245","first-page":"442","article-title":"Hypoglycemias.","volume":"154","author":"Service","year":"1991","journal-title":"West J Med"},{"key":"2019041122111949200_R246","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0025-7125(16)30081-5","article-title":"Hypoglycemia.","volume":"79","author":"Service","year":"1995","journal-title":"Med Clin North Am"},{"key":"2019041122111949200_R247","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199504273321707","article-title":"Hypoglycemic disorders.","volume":"332","author":"Service","year":"1995","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R248","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1210\/jcem.85.9.6807","article-title":"Forty-eight-hour fast: the diagnostic test for insulinoma.","volume":"85","author":"Hirshberg","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R249","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0889-8529(05)70085-2","article-title":"Classification of hypoglycemic disorders.","volume":"28","author":"Service","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R250","first-page":"1048","article-title":"Proinsulin by immunochemiluminometric assay for the diagnosis of insulinoma.","volume":"78","author":"Kao","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R251","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1001\/archinte.1985.00360100127021","article-title":"Anomalous glucose and insulin responses in patients with insulinoma. Caveats for diagnosis.","volume":"145","author":"Dons","year":"1985","journal-title":"Arch Intern Med"},{"key":"2019041122111949200_R252","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1046\/j.1365-2168.2000.01277.x","article-title":"Neuroendocrine tumours of the pancreas.","volume":"87","author":"Eriksson","year":"2000","journal-title":"Br J Surg"},{"key":"2019041122111949200_R253","doi-asserted-by":"crossref","first-page":"269","DOI":"10.7326\/0003-4819-123-4-199508150-00004","article-title":"Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium.","volume":"123","author":"Doppman","year":"1995","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R254","first-page":"1623","article-title":"Localization of insulinomas by selective intraarterial calcium injection.","volume":"81","author":"O\u2019Shea","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R255","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1530\/eje.0.1390532","article-title":"Dose-related effects of growth hormone on IGF-I and IGF-binding protein-3 levels in non-islet cell tumour hypoglycaemia.","volume":"139","author":"Drake","year":"1998","journal-title":"Eur J Endocrinol"},{"key":"2019041122111949200_R256","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s11864-003-0006-y","article-title":"Insulinoma.","volume":"4","author":"Burns","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"2019041122111949200_R257","first-page":"1027","article-title":"Metastatic insulin-secreting carcinoma of the pancreas: clinical course and the role of surgery.","volume":"96","author":"Danforth Jr","year":"1984","journal-title":"Surgery"},{"key":"2019041122111949200_R258","first-page":"1582","article-title":"Noninsulinoma pancreatogenous hypoglycemia: a novel syndrome of hyperinsulinemic hypoglycemia in adults independent of mutations in Kir6.2 and SUR1 genes.","volume":"84","author":"Service","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R259","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1046\/j.1365-2362.2003.01158.x","article-title":"Nesidioblastosis in adults: a challenging cause of organic hyperinsulinism.","volume":"33","author":"Kaczirek","year":"2003","journal-title":"Eur J Clin Invest"},{"key":"2019041122111949200_R260","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJM198711053171907","article-title":"Zollinger-Ellison syndrome. Current concepts in diagnosis and management.","volume":"317","author":"Wolfe","year":"1987","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R261","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1056\/NEJM198206243062506","article-title":"Extrapancreatic, extraintestinal gastrinoma: effective treatment by surgery.","volume":"306","author":"Wolfe","year":"1982","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R262","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0889-8529(18)30380-3","article-title":"Diagnosis and management of Zollinger-Ellison syndrome.","volume":"18","author":"Maton","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R263","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S0003-4975(98)01205-3","article-title":"Surgical resection of intracardiac gastrinoma.","volume":"67","author":"Noda","year":"1999","journal-title":"Ann Thorac Surg"},{"key":"2019041122111949200_R264","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1097\/00005792-200011000-00004","article-title":"Zollinger-Ellison syndrome. Clinical presentation in 261 patients.","volume":"79","author":"Roy","year":"2000","journal-title":"Medicine (Baltimore)"},{"key":"2019041122111949200_R265","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM198607033150101","article-title":"Cushing\u2019s syndrome in patients with the Zollinger-Ellison syndrome.","volume":"315","author":"Maton","year":"1986","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R266","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01654904","article-title":"Thirty years\u2019 experience with gastrinoma.","volume":"8","author":"Zollinger","year":"1984","journal-title":"World J Surg"},{"key":"2019041122111949200_R267","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0002-9343(94)90323-9","article-title":"Zollinger-Ellison syndrome can be the initial endocrine manifestation in patients with multiple endocrine neoplasia-type I.","volume":"97","author":"Benya","year":"1994","journal-title":"Am J Med"},{"key":"2019041122111949200_R268","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/0016-5085(95)90124-8","article-title":"Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study.","volume":"108","author":"Weber","year":"1995","journal-title":"Gastroenterology"},{"key":"2019041122111949200_R269","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.1994.03510420061035","article-title":"Zollinger-Ellison syndrome. Advances in treatment of gastric hypersecretion and the gastrinoma.","volume":"271","author":"Jensen","year":"1994","journal-title":"JAMA"},{"key":"2019041122111949200_R270","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/S0039-6109(16)46637-5","article-title":"Advances in the management of patients with Zollinger-Ellison syndrome.","volume":"75","author":"Orloff","year":"1995","journal-title":"Surg Clin North Am"},{"key":"2019041122111949200_R271","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1016\/0016-5085(80)90933-6","article-title":"Secretin injection test in the diagnosis of gastrinoma.","volume":"79","author":"McGuigan","year":"1980","journal-title":"Gastroenterology"},{"key":"2019041122111949200_R272","doi-asserted-by":"crossref","first-page":"713","DOI":"10.7326\/0003-4819-111-9-713","article-title":"Secretin and calcium provocative tests in the Zollinger-Ellison syndrome. A prospective study.","volume":"111","author":"Frucht","year":"1989","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R273","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00005792-200105000-00005","article-title":"Gastric secretion in Zollinger-Ellison syndrome. Correlation with clinical expression, tumor extent and role in diagnosis\u2013a prospective NIH study of 235 patients and a review of 984 cases in the literature.","volume":"80","author":"Roy","year":"2001","journal-title":"Medicine (Baltimore)"},{"key":"2019041122111949200_R274","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s002689900448","article-title":"Localization, malignant potential, and surgical management of gastrinomas.","volume":"22","author":"Kisker","year":"1998","journal-title":"World J Surg"},{"key":"2019041122111949200_R275","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1210\/jcem-73-2-281","article-title":"Multiple endocrine neoplasia type 1: a 10-year prospective screening study in four kindreds.","volume":"73","author":"Skogseid","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R276","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0950-3528(96)90019-6","article-title":"Gastrointestinal endocrine tumours. Glucagonomas.","volume":"10","author":"Frankton","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2019041122111949200_R277","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/00005792-199603000-00002","article-title":"The glucagonoma syndrome. Clinical and pathologic features in 21 patients.","volume":"75","author":"Wermers","year":"1996","journal-title":"Medicine (Baltimore)"},{"key":"2019041122111949200_R278","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00000441-200105000-00003","article-title":"The glucagonoma syndrome: a review of its features and discussion of new perspectives.","volume":"321","author":"Chastain","year":"2001","journal-title":"Am J Med Sci"},{"key":"2019041122111949200_R279","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/S0002-9610(05)80761-5","article-title":"Glucagonoma syndrome is an underdiagnosed clinical entity.","volume":"160","author":"Edney","year":"1990","journal-title":"Am J Surg"},{"key":"2019041122111949200_R280","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1210\/edrv-2-3-347","article-title":"The glucagonoma syndrome: clinical features, diagnosis, and treatment.","volume":"2","author":"Stacpoole","year":"1981","journal-title":"Endocr Rev"},{"key":"2019041122111949200_R281","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1016\/0002-9343(81)90858-5","article-title":"A familial glucagonoma syndrome: genetic, clinical and biochemical features.","volume":"70","author":"Stacpoole","year":"1981","journal-title":"Am J Med"},{"key":"2019041122111949200_R282","first-page":"125","article-title":"Clinical aspects of glucagon-producing islet cell tumors.","volume":"76","author":"Prinz","year":"1981","journal-title":"Am J Gastroenterol"},{"key":"2019041122111949200_R283","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archinte.1980.00330140120030","article-title":"The glucagonoma syndrome. Report of a case.","volume":"140","author":"Domen","year":"1980","journal-title":"Arch Intern Med"},{"key":"2019041122111949200_R284","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-4632.2004.01844.x","article-title":"Necrolytic migratory erythema: clinicopathologic study of 13 cases.","volume":"43","author":"Pujol","year":"2004","journal-title":"Int J Dermatol"},{"key":"2019041122111949200_R285","first-page":"389","article-title":"Vipoma\/diarrheogenic syndrome: a statistical evaluation of 241 reported cases.","volume":"17","author":"Soga","year":"1998","journal-title":"J Exp Clin Cancer Res"},{"key":"2019041122111949200_R286","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S0950-3528(96)90018-4","article-title":"Vasoactive intestinal polypeptide-secreting tumours: biology and therapy.","volume":"10","author":"Park","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2019041122111949200_R287","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0039-6109(16)44190-3","article-title":"Update on the diagnosis and treatment of rare neuroendocrine tumors.","volume":"67","author":"Friesen","year":"1987","journal-title":"Surg Clin North Am"},{"key":"2019041122111949200_R288","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0889-8529(18)30381-5","article-title":"Medical therapy of VIPomas.","volume":"18","author":"O\u2019Dorisio","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R289","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/00006676-200401000-00015","article-title":"Diagnosis and treatment of VIPoma in China (case report and 31 cases review): diagnosis and treatment of VIPoma.","volume":"28","author":"Peng","year":"2004","journal-title":"Pancreas"},{"key":"2019041122111949200_R290","first-page":"13","article-title":"Somatostatinoma\/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas.","volume":"18","author":"Soga","year":"1999","journal-title":"J Exp Clin Cancer Res"},{"key":"2019041122111949200_R291","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/jso.2930360104","article-title":"Somatostatinoma: a case report and review of the literature.","volume":"36","author":"Harris","year":"1987","journal-title":"J Surg Oncol"},{"key":"2019041122111949200_R292","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/jso.2930590116","article-title":"Von Recklinghausen\u2019s disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas.","volume":"59","author":"Mao","year":"1995","journal-title":"J Surg Oncol"},{"key":"2019041122111949200_R293","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/00000478-198605000-00007","article-title":"Duodenal carcinoids in patients with and without neurofibromatosis. A comparative study.","volume":"10","author":"Dayal","year":"1986","journal-title":"Am J Surg Pathol"},{"key":"2019041122111949200_R294","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1210\/jcem-52-5-886","article-title":"Malignant somatostatinoma: clinical features and metabolic studies.","volume":"52","author":"Axelrod","year":"1981","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R295","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1046\/j.1440-1827.2000.01016.x","article-title":"Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis.","volume":"50","author":"Tanaka","year":"2000","journal-title":"Pathol Int"},{"key":"2019041122111949200_R296","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJMoa022384","article-title":"Ectopic luteinizing hormone secretion and anovulation.","volume":"348","author":"Hirshberg","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R297","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1210\/jc.2002-021842","article-title":"Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma.","volume":"88","author":"Corbetta","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R298","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1002\/1097-0142(19900115)65:2<354::AID-CNCR2820650229>3.0.CO;2-N","article-title":"Islet cell carcinoma of the pancreas. A study of 98 patients.","volume":"65","author":"Venkatesh","year":"1990","journal-title":"Cancer"},{"key":"2019041122111949200_R299","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s002689900134","article-title":"Islet cell carcinoma of the pancreas.","volume":"20","author":"Lo","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R300","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1007\/s002680010234","article-title":"Management of nonfunctioning islet cell carcinomas.","volume":"24","author":"Bartsch","year":"2000","journal-title":"World J Surg"},{"key":"2019041122111949200_R301","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0011-3840(94)90079-5","article-title":"Neuroendocrine tumors of the pancreas and duodenum.","volume":"31","author":"Norton","year":"1994","journal-title":"Curr Probl Surg"},{"key":"2019041122111949200_R302","first-page":"1175","article-title":"Nonfunctioning islet cell carcinoma of the pancreas.","volume":"114","author":"Evans","year":"1993","journal-title":"Surgery"},{"key":"2019041122111949200_R303","first-page":"285","article-title":"High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications.","volume":"61","author":"Rigaud","year":"2001","journal-title":"Cancer Res"},{"key":"2019041122111949200_R304","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/00000658-199608000-00002","article-title":"The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors.","volume":"224","author":"Eijck","year":"1996","journal-title":"Ann Surg"},{"key":"2019041122111949200_R305","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJM199003153221103","article-title":"Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type 1 and the Zollinger-Ellison syndrome.","volume":"322","author":"Pipeleers-Marichal","year":"1990","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R306","first-page":"S195","article-title":"Intra-operative procedures to localize endocrine tumours of the pancreas and duodenum.","volume":"31(Suppl 2)","author":"Norton","year":"1999","journal-title":"Ital J Gastroenterol Hepatol"},{"key":"2019041122111949200_R307","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s002689900133","article-title":"Surgery for asymptomatic pancreatic lesion in multiple endocrine neoplasia type I.","volume":"20","author":"Skogseid","year":"1996","journal-title":"World J Surg"},{"key":"2019041122111949200_R308","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3109\/02841869109092405","article-title":"Genetic and clinical characteristics of multiple endocrine neoplasia type 1.","volume":"30","author":"Skogseid","year":"1991","journal-title":"Acta Oncol"},{"key":"2019041122111949200_R309","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1210\/jcem-64-6-1233","article-title":"A standardized meal stimulation test of the endocrine pancreas for early detection of pancreatic endocrine tumors in multiple endocrine neoplasia type 1 syndrome: five years experience.","volume":"64","author":"Skogseid","year":"1987","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R310","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1200\/JCO.1999.17.2.615","article-title":"Prospective study of the clinical course, prognostic factors, causes of death, and survival in patients with long-standing Zollinger-Ellison syndrome.","volume":"17","author":"Yu","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R311","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1148\/radiology.216.1.r00jl26163","article-title":"Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection.","volume":"216","author":"Ichikawa","year":"2000","journal-title":"Radiology"},{"key":"2019041122111949200_R312","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1148\/radiographics.17.2.9084084","article-title":"Islet cell tumors of the pancreas: clinical, radiologic, and pathologic correlation in diagnosis and localization.","volume":"17","author":"Buetow","year":"1997","journal-title":"Radiographics"},{"key":"2019041122111949200_R313","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0009-9260(05)81790-8","article-title":"Imaging islet cell tumours.","volume":"49","author":"King","year":"1994","journal-title":"Clin Radiol"},{"key":"2019041122111949200_R314","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/gut.39.4.562","article-title":"Endoscopic ultrasonography and somatostatin receptor scintigraphy in the preoperative localisation of insulinomas and gastrinomas.","volume":"39","author":"Zimmer","year":"1996","journal-title":"Gut"},{"key":"2019041122111949200_R315","first-page":"XX","article-title":"[Screening for hereditary neuroendocrine tumors of the gastrointestinal-pancreatic system].","volume":"34","author":"Scherubl","year":"1996","journal-title":"Z Gastroenterol"},{"key":"2019041122111949200_R316","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/00000658-199808000-00013","article-title":"Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome.","volume":"228","author":"Alexander","year":"1998","journal-title":"Ann Surg"},{"key":"2019041122111949200_R317","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S0016-5085(96)70052-5","article-title":"Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Groupe D\u2019etude Du Syndrome De Zollinger-Ellison.","volume":"111","author":"Cadiot","year":"1996","journal-title":"Gastroenterology"},{"key":"2019041122111949200_R318","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0039-6060(05)80121-7","article-title":"Indium-111-pentetreotide scanning versus conventional imaging techniques for the localization of gastrinoma.","volume":"118","author":"Schirmer","year":"1995","journal-title":"Surgery"},{"key":"2019041122111949200_R319","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1093\/annonc\/12.suppl_2.S51","article-title":"Nuclear medicine imaging of neuroendocrine tumours.","volume":"12(Suppl 2)","author":"Bombardieri","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R320","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1148\/radiology.214.2.r00fe32483","article-title":"Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity.","volume":"214","author":"Thoeni","year":"2000","journal-title":"Radiology"},{"key":"2019041122111949200_R321","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1148\/radiology.178.3.1994415","article-title":"Zollinger-Ellison syndrome: prospective assessment of abdominal US in the localization of gastrinomas.","volume":"178","author":"London","year":"1991","journal-title":"Radiology"},{"key":"2019041122111949200_R322","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1056\/NEJM199206253262601","article-title":"Localization of pancreatic endocrine tumors by endoscopic ultrasonography.","volume":"326","author":"Rosch","year":"1992","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R323","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/gut.33.1.108","article-title":"Endoscopic ultrasound for localisation of islet cell tumours.","volume":"33","author":"Glover","year":"1992","journal-title":"Gut"},{"key":"2019041122111949200_R324","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1111\/j.1572-0241.2000.02480.x","article-title":"Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas.","volume":"95","author":"Anderson","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2019041122111949200_R325","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0016-5107(99)70440-2","article-title":"Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors.","volume":"49","author":"Bansal","year":"1999","journal-title":"Gastrointest Endosc"},{"key":"2019041122111949200_R326","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0039-6060(95)80005-0","article-title":"Localization of gastrinomas by endoscopic ultrasonography in patients with Zollinger-Ellison syndrome.","volume":"117","author":"Ruszniewski","year":"1995","journal-title":"Surgery"},{"key":"2019041122111949200_R327","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.2214\/ajr.165.6.7484581","article-title":"Helical CT for the preoperative localization of islet cell tumors of the pancreas: value of arterial and parenchymal phase images.","volume":"165","author":"Van Hoe","year":"1995","journal-title":"AJR Am J Roentgenol"},{"key":"2019041122111949200_R328","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.2214\/ajr.170.5.9574609","article-title":"Pancreatic tumors: comparison of dual-phase helical CT and endoscopic sonography.","volume":"170","author":"Legmann","year":"1998","journal-title":"AJR Am J Roentgenol"},{"key":"2019041122111949200_R329","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1259\/bjr.74.886.740968","article-title":"MRI of pancreatic neuroendocrine tumours.","volume":"74","author":"Owen","year":"2001","journal-title":"Br J Radiol"},{"key":"2019041122111949200_R330","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1148\/radiology.186.3.8381551","article-title":"Islet cell tumors: comparison of dynamic contrast-enhanced CT and MR imaging with dynamic gadolinium enhancement and fat suppression.","volume":"186","author":"Semelka","year":"1993","journal-title":"Radiology"},{"key":"2019041122111949200_R331","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1259\/bjr.74.887.741065","article-title":"Imaging appearances of metastases from neuroendocrine tumours of the pancreas.","volume":"74","author":"Debray","year":"2001","journal-title":"Br J Radiol"},{"key":"2019041122111949200_R332","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1046\/j.1365-2265.2001.01335.x","article-title":"Assessment of selective arterial calcium stimulation and hepatic venous sampling to localize insulin-secreting tumours.","volume":"55","author":"Brandle","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R333","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1001\/archsurg.1992.01420040088015","article-title":"Surgical approach to insulinomas. Assessing the need for preoperative localization.","volume":"127","author":"Pasieka","year":"1992","journal-title":"Arch Surg"},{"key":"2019041122111949200_R334","first-page":"1086","article-title":"Location, incidence, and malignant potential of duodenal gastrinomas.","volume":"110","author":"Thom","year":"1991","journal-title":"Surgery"},{"key":"2019041122111949200_R335","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2796.1998.00340.x","article-title":"Somatostatin receptor expression in multiple endocrine neoplasia and in von Hippel-Lindau disease.","volume":"243","author":"Lamberts","year":"1998","journal-title":"J Intern Med"},{"key":"2019041122111949200_R336","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1046\/j.1365-2362.1997.1740719.x","article-title":"Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours.","volume":"27","author":"Jais","year":"1997","journal-title":"Eur J Clin Invest"},{"key":"2019041122111949200_R337","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/BF02067335","article-title":"Pancreatic tumors in multiple endocrine neoplasia type 1: clinical presentation and surgical treatment.","volume":"16","author":"Grama","year":"1992","journal-title":"World J Surg"},{"key":"2019041122111949200_R338","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0889-8529(18)30378-5","article-title":"Management of pheochromocytoma.","volume":"18","author":"Shapiro","year":"1989","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R339","first-page":"1823","article-title":"131I-MIBG therapy of neural crest tumours (review).","volume":"17","author":"Troncone","year":"1997","journal-title":"Anticancer Res"},{"key":"2019041122111949200_R340","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1210\/jcem.86.11.8034","article-title":"Benign paragangliomas: clinical presentation and treatment outcomes in 236 patients.","volume":"86","author":"Erickson","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R341","first-page":"637","article-title":"A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology.","volume":"85","author":"Mantero","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R342","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1210\/er.2002-0013","article-title":"Pheochromocytoma: state-of-the-art and future prospects.","volume":"24","author":"Bravo","year":"2003","journal-title":"Endocr Rev"},{"key":"2019041122111949200_R343","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1210\/jc.2003-030720","article-title":"Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience.","volume":"88","author":"Kudva","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R344","first-page":"223","author":"Grossman","year":"2003"},{"key":"2019041122111949200_R345","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/BF03345807","article-title":"Malignant pheochromocytoma: clinical, biological, histologic and therapeutic data in a series of 20 patients with distant metastases.","volume":"15","author":"Schlumberger","year":"1992","journal-title":"J Endocrinol Invest"},{"key":"2019041122111949200_R346","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1464-410X.1985.tb06295.x","article-title":"Malignant phaeochromocytoma.","volume":"57","author":"Lewi","year":"1985","journal-title":"Br J Urol"},{"key":"2019041122111949200_R347","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/BF03348026","article-title":"The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients.","volume":"20","author":"Loh","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"2019041122111949200_R348","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1365-2265.1984.tb00074.x","article-title":"Malignant phaeochromocytoma: clinical, biochemical and scintigraphic characterization.","volume":"20","author":"Shapiro","year":"1984","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R349","first-page":"576","article-title":"Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases.","volume":"26","author":"Shapiro","year":"1985","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R350","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1055\/s-0029-1212001","article-title":"Malignant pheochromocytoma.","volume":"106","author":"Mundschenk","year":"1998","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2019041122111949200_R351","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/00000658-199906000-00001","article-title":"Clinical experience over 48 years with pheochromocytoma.","volume":"229","author":"Goldstein","year":"1999","journal-title":"Ann Surg"},{"key":"2019041122111949200_R352","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1056\/NEJM199609263351307","article-title":"Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung\u2019s disease.","volume":"335","author":"Eng","year":"1996","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R353","first-page":"1736","article-title":"The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome.","volume":"59","author":"Ponder","year":"1999","journal-title":"Cancer Res"},{"key":"2019041122111949200_R354","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S0022-5347(05)68171-2","article-title":"von Recklinghausen\u2019s disease and pheochromocytomas.","volume":"162","author":"Walther","year":"1999","journal-title":"J Urol"},{"key":"2019041122111949200_R355","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1055-3207(18)30244-8","article-title":"Benign and malignant pheochromocytoma: diagnosis, treatment, and follow-up.","volume":"7","author":"Kebebew","year":"1998","journal-title":"Surg Oncol Clin N Am"},{"key":"2019041122111949200_R356","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00001622-200401000-00003","article-title":"Pheochromocytoma and functional paraganglioma.","volume":"16","author":"Roman","year":"2004","journal-title":"Curr Opin Oncol"},{"key":"2019041122111949200_R357","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s11864-001-0025-5","article-title":"Pheochromocytoma.","volume":"2","author":"Eigelberger","year":"2001","journal-title":"Curr Treat Options Oncol"},{"key":"2019041122111949200_R358","first-page":"1153","article-title":"Pheochromocytoma\u2013continuing evolution of surgical therapy.","volume":"114","author":"Orchard","year":"1993","journal-title":"Surgery"},{"key":"2019041122111949200_R359","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1136\/pgmj.60.700.111","article-title":"Phaeochromocytoma and acute cardiovascular death (with special reference to myocardial infarction).","volume":"60","author":"Cohen","year":"1984","journal-title":"Postgrad Med J"},{"key":"2019041122111949200_R360","doi-asserted-by":"crossref","first-page":"315","DOI":"10.7326\/0003-4819-134-4-200102200-00016","article-title":"Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma.","volume":"134","author":"Pacak","year":"2001","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R361","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1159\/000074659","article-title":"Biochemical diagnosis of pheochromocytoma.","volume":"31","author":"Eisenhofer","year":"2004","journal-title":"Front Horm Res"},{"key":"2019041122111949200_R362","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/BF01658516","article-title":"Long-term evaluation following resection of apparently benign pheochromocytoma(s)\/paraganglioma(s).","volume":"14","author":"Heerden","year":"1990","journal-title":"World J Surg"},{"key":"2019041122111949200_R363","first-page":"145","article-title":"Prognosis of children with malignant pheochromocytoma. Report of 2 cases and review of the literature.","volume":"52","author":"Coutant","year":"1999","journal-title":"Horm Res"},{"key":"2019041122111949200_R364","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1161\/01.HYP.36.6.1045","article-title":"Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment.","volume":"36","author":"Rao","year":"2000","journal-title":"Hypertension"},{"key":"2019041122111949200_R365","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1159\/000074663","article-title":"Malignant pheochromocytoma.","volume":"31","author":"Lehnert","year":"2004","journal-title":"Front Horm Res"},{"key":"2019041122111949200_R366","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000074658","article-title":"The clinical presentation (symptoms and signs) of sporadic and familial chromaffin cell tumours (phaeochromocytomas and paragangliomas).","volume":"31","author":"Kaltsas","year":"2004","journal-title":"Front Horm Res"},{"key":"2019041122111949200_R367","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1148\/radiology.202.1.8988215","article-title":"Pheochromocytoma: effect of nonionic contrast medium in CT on circulating catecholamine levels.","volume":"202","author":"Mukherjee","year":"1997","journal-title":"Radiology"},{"key":"2019041122111949200_R368","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1046\/j.1365-2265.1998.00475.x","article-title":"Imaging of incidentally discovered adrenal masses.","volume":"48","author":"Peppercorn","year":"1998","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R369","first-page":"365","article-title":"Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison.","volume":"40","author":"Maurea","year":"1996","journal-title":"Q J Nucl Med"},{"key":"2019041122111949200_R370","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1365-2265.1991.tb03496.x","article-title":"The use of venous catheterization in the diagnosis and localization of bilateral phaeochromocytomas.","volume":"35","author":"Newbould","year":"1991","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R371","first-page":"3641","article-title":"A \u201cpheo\u201d lurks: novel approaches for locating occult pheochromocytoma.","volume":"86","author":"Pacak","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R372","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1126\/science.287.5454.848","article-title":"Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma.","volume":"287","author":"Baysal","year":"2000","journal-title":"Science"},{"key":"2019041122111949200_R373","first-page":"4101","article-title":"Sporadic pheochromocytomas are rarely associated with germline mutations in the vhl tumor suppressor gene or the ret protooncogene.","volume":"82","author":"Brauch","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R374","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2265.1995.tb02593.x","article-title":"Absence of mutations in the MEN2A region of the ret proto-oncogene in non-MEN 2A phaeochromocytomas.","volume":"42","author":"Chew","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R375","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1002\/(SICI)1097-0142(19980101)82:1<176::AID-CNCR22>3.0.CO;2-Z","article-title":"Elevated levels of telomerase activity in malignant pheochromocytoma.","volume":"82","author":"Kubota","year":"1998","journal-title":"Cancer"},{"key":"2019041122111949200_R376","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1385\/EP:13:2:149","article-title":"Prediction of malignant behavior of pheochromocytomas and paragangliomas using immunohistochemical techniques.","volume":"13","author":"Kumaki","year":"2002","journal-title":"Endocr Pathol"},{"key":"2019041122111949200_R377","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.1210\/jcem.86.11.8052","article-title":"Increased expression of cyclooxygenase-2 in malignant pheochromocytomas.","volume":"86","author":"Salmenkivi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R378","first-page":"2231","article-title":"Inhibin\/activin \u03b2B-subunit expression in pheochromocytomas favors benign diagnosis.","volume":"86","author":"Salmenkivi","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R379","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s004230050143","article-title":"German medullary thyroid carcinoma\/multiple endocrine neoplasia registry. German MTC\/MEN Study Group. Medullary Thyroid Carcinoma\/Multiple Endocrine Neoplasia Type 2.","volume":"383","author":"Raue","year":"1998","journal-title":"Langenbecks Arch Surg"},{"key":"2019041122111949200_R380","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11864-000-0052-7","article-title":"Medullary thyroid cancer.","volume":"1","author":"Kebebew","year":"2000","journal-title":"Curr Treat Options Oncol"},{"key":"2019041122111949200_R381","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1139::AID-CNCR26>3.0.CO;2-Z","article-title":"Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems.","volume":"88","author":"Kebebew","year":"2000","journal-title":"Cancer"},{"key":"2019041122111949200_R382","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1677\/erc.0.0080135","article-title":"Treatment of medullary thyroid carcinoma: an update.","volume":"8","author":"Orlandi","year":"2001","journal-title":"Endocr Relat Cancer"},{"key":"2019041122111949200_R383","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1023\/A:1008242302749","article-title":"Current diagnosis and management of medullary thyroid carcinoma.","volume":"9","author":"Giuffrida","year":"1998","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R384","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1210\/jcem-39-3-487","article-title":"A comparison of pentagastrin injection and calcium infusion as provocative agents for the detection of medullary carcinoma of the thyroid.","volume":"39","author":"Hennessy","year":"1974","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R385","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1056\/NEJMoa012915","article-title":"Early malignant progression of hereditary medullary thyroid cancer.","volume":"349","author":"Machens","year":"2003","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R386","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1067\/S0039-6060(03)00157-0","article-title":"Malignant progression from C-cell hyperplasia to medullary thyroid carcinoma in 167 carriers of RET germline mutations.","volume":"134","author":"Machens","year":"2003","journal-title":"Surgery"},{"key":"2019041122111949200_R387","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0889-8529(05)70315-7","article-title":"Surgical considerations and approach to thyroid cancer.","volume":"25","author":"Soh","year":"1996","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R388","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1210\/jcem.85.2.6556","article-title":"Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d\u2019Etudes des Tumeurs a Calcitonine (GETC).","volume":"85","author":"Cohen","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R389","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/(SICI)1097-0142(19960415)77:8<1556::AID-CNCR20>3.0.CO;2-Y","article-title":"Multivariate analysis of patients with medullary thyroid carcinoma. Prognostic significance and impact on treatment of clinical and pathologic variables.","volume":"77","author":"Dottorini","year":"1996","journal-title":"Cancer"},{"key":"2019041122111949200_R390","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jcem.82.5.3949","article-title":"Routine measurement of plasma calcitonin in nodular thyroid diseases.","volume":"82","author":"Vierhapper","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R391","doi-asserted-by":"crossref","first-page":"118","DOI":"10.7326\/0003-4819-122-2-199501150-00008","article-title":"Genetic testing in the diagnosis and management of multiple endocrine neoplasia type II.","volume":"122","author":"Ledger","year":"1995","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R392","first-page":"1890","article-title":"Improved diagnostic methods in the follow-up of medullary thyroid carcinoma by highly specific calcitonin measurements.","volume":"85","author":"Engelbach","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R393","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1001\/archsurg.135.8.895","article-title":"Long-term results of reoperation and localizing studies in patients with persistent or recurrent medullary thyroid cancer.","volume":"135","author":"Kebebew","year":"2000","journal-title":"Arch Surg"},{"key":"2019041122111949200_R394","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ssu.1044","article-title":"Minimal residual disease in thyroid carcinoma.","volume":"20","author":"Weber","year":"2001","journal-title":"Semin Surg Oncol"},{"key":"2019041122111949200_R395","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/00006231-199306000-00006","article-title":"The potential value of somatostatin receptor scintigraphy in medullary thyroid carcinoma.","volume":"14","author":"Dorr","year":"1993","journal-title":"Nucl Med Commun"},{"key":"2019041122111949200_R396","first-page":"273","article-title":"Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma.","volume":"25","author":"Rufini","year":"2000","journal-title":"Rays"},{"key":"2019041122111949200_R397","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12+<2436::AID-CNCR16>3.0.CO;2-D","article-title":"Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?","volume":"80","author":"Behr","year":"1997","journal-title":"Cancer"},{"key":"2019041122111949200_R398","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/bjc.1994.224","article-title":"Selective venous sampling catheterisation for localisation of persisting medullary thyroid carcinoma.","volume":"69","author":"Abdelmoumene","year":"1994","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R399","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1097\/00000658-199706000-00011","article-title":"Improved results of cervical reoperation for medullary thyroid carcinoma.","volume":"225","author":"Moley","year":"1997","journal-title":"Ann Surg"},{"key":"2019041122111949200_R400","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/BF03348014","article-title":"Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma.","volume":"20","author":"Gasparoni","year":"1997","journal-title":"J Endocrinol Invest"},{"key":"2019041122111949200_R401","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000201400","article-title":"Control of growth in neuroendocrine gastro-enteropancreatic tumours.","volume":"57(Suppl 1)","author":"Arnold","year":"1996","journal-title":"Digestion"},{"key":"2019041122111949200_R402","first-page":"1346","article-title":"[Therapy of metastatic endocrine tumors of the gastrointestinal tract].","volume":"121","author":"Arnold","year":"1996","journal-title":"Dtsch Med Wochenschr"},{"key":"2019041122111949200_R403","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199908263410902","article-title":"Surgery to cure the Zollinger-Ellison syndrome.","volume":"341","author":"Norton","year":"1999","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R404","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1093\/annonc\/10.suppl_2.S3","article-title":"Neuroendocrine gastrointestinal tumors\u2013a condensed overview of diagnosis and treatment.","volume":"10(Suppl 2)","author":"Oberg","year":"1999","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R405","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0950-3528(96)90021-4","article-title":"Gastrointestinal endocrine tumours: medical management.","volume":"10","author":"Arnold","year":"1996","journal-title":"Baillieres Clin Gastroenterol"},{"key":"2019041122111949200_R406","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00268-002-6630-z","article-title":"Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases.","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"key":"2019041122111949200_R407","first-page":"3745","article-title":"[Therapeutic alternative in metastasizing neuroendocrine tumors. In carefully selected cases liver transplantation is possible].","volume":"96","author":"Oberg","year":"1999","journal-title":"Lakartidningen"},{"key":"2019041122111949200_R408","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.surg.2003.07.025","article-title":"Aggressive surgery for metastatic liver neuroendocrine tumors.","volume":"134","author":"Norton","year":"2003","journal-title":"Surgery"},{"key":"2019041122111949200_R409","first-page":"284","article-title":"Treatment of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: a French multicenter study.","volume":"35","author":"Krempf","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R410","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1210\/jcem-72-2-455","article-title":"Use of m-[131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma.","volume":"72","author":"Krempf","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R411","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000051475","article-title":"The role of octreotide in the treatment of gastroenteropancreatic endocrine tumors.","volume":"60(Suppl 2)","author":"Degen","year":"1999","journal-title":"Digestion"},{"key":"2019041122111949200_R412","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1093\/annonc\/10.suppl_2.S31","article-title":"Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook.","volume":"10(Suppl 2)","author":"Eriksson","year":"1999","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R413","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1200\/JCO.1983.1.11.727","article-title":"Treatment of the carcinoid tumor and the malignant carcinoid syndrome.","volume":"1","author":"Moertel","year":"1983","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R414","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2036.1993.tb00122.x","article-title":"Review article: the management of Zollinger-Ellison syndrome.","volume":"7","author":"Maton","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"2019041122111949200_R415","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/j.1365-2036.1993.tb00140.x","article-title":"Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety.","volume":"7","author":"Metz","year":"1993","journal-title":"Aliment Pharmacol Ther"},{"key":"2019041122111949200_R416","first-page":"34","article-title":"Effect of somatostatin on skin lesions and concentrations of plasma amino acids in a patient with glucagonoma-syndrome.","volume":"35","author":"Schmid","year":"1988","journal-title":"Hepatogastroenterology"},{"key":"2019041122111949200_R417","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-3-642-80035-1_12","article-title":"Drug therapy in metastatic neuroendocrine tumors of the gastroenteropancreatic system.","volume":"142","author":"Faiss","year":"1996","journal-title":"Recent Results Cancer Res"},{"key":"2019041122111949200_R418","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1159\/000201404","article-title":"Interferon-\u03b1 versus somatostatin or the combination of both in metastatic neuroendocrine gut and pancreatic tumours.","volume":"57(Suppl 1)","author":"Faiss","year":"1996","journal-title":"Digestion"},{"key":"2019041122111949200_R419","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000049160","article-title":"Established clinical use of octreotide and lanreotide in oncology.","volume":"47(Suppl 2)","author":"Oberg","year":"2001","journal-title":"Chemotherapy"},{"key":"2019041122111949200_R420","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/1097-0142(19930701)72:1<244::AID-CNCR2820720143>3.0.CO;2-Q","article-title":"Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors.","volume":"72","author":"Saltz","year":"1993","journal-title":"Cancer"},{"key":"2019041122111949200_R421","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1159\/000007693","article-title":"Ultra-high-dose lanreotide treatment in patients with metastatic neuroendocrine gastroenteropancreatic tumors.","volume":"60","author":"Faiss","year":"1999","journal-title":"Digestion"},{"key":"2019041122111949200_R422","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00001622-199901000-00008","article-title":"Recent advances in systemic therapy for gastrointestinal neuroendocrine tumors.","volume":"11","author":"Pelley","year":"1999","journal-title":"Curr Opin Oncol"},{"key":"2019041122111949200_R423","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1093\/annonc\/12.suppl_2.S111","article-title":"Chemotherapy and biotherapy in the treatment of neuroendocrine tumours.","volume":"12(Suppl 2)","author":"Oberg","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R424","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/S0959-8049(01)00073-9","article-title":"Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.","volume":"37","author":"Aparicio","year":"2001","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R425","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/00000421-199806000-00007","article-title":"Carcinoid tumor regression with high-dose octreotide acetate: a patient report.","volume":"21","author":"Lokich","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"2019041122111949200_R426","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jso.10062","article-title":"Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature.","volume":"79","author":"Leong","year":"2002","journal-title":"J Surg Oncol"},{"key":"2019041122111949200_R427","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1046\/j.1365-2265.2000.01126.x","article-title":"Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.","volume":"53","author":"Imtiaz","year":"2000","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R428","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJM200008243430805","article-title":"Treatment of type II gastric carcinoid tumors with somatostatin analogues.","volume":"343","author":"Tomassetti","year":"2000","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R429","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/0959-8049(94)90065-5","article-title":"Treatment of the carcinoid syndrome with a depot formulation of the somatostatin analogue lanreotide.","volume":"30A","author":"Scherubl","year":"1994","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R430","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1177\/030089169307900602","article-title":"Medical treatment of neuroendocrine tumors.","volume":"79","author":"Bajetta","year":"1993","journal-title":"Tumori"},{"key":"2019041122111949200_R431","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/(SICI)1097-0142(19960115)77:2<402::AID-CNCR25>3.0.CO;2-4","article-title":"Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.","volume":"77","author":"Di Bartolomeo","year":"1996","journal-title":"Cancer"},{"key":"2019041122111949200_R432","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1136\/gut.39.2.279","article-title":"Treatment of the carcinoid syndrome with the long-acting somatostatin analogue lanreotide: a prospective study in 39 patients.","volume":"39","author":"Ruszniewski","year":"1996","journal-title":"Gut"},{"key":"2019041122111949200_R433","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1023\/A:1008205415035","article-title":"High-dose treatment with lanreotide of patients with advanced neuroendocrine gastrointestinal tumors: clinical and biological effects.","volume":"8","author":"Eriksson","year":"1997","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R434","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1111\/j.1572-0241.1998.465_q.x","article-title":"Slow-release lanreotide treatment in endocrine gastrointestinal tumors.","volume":"93","author":"Tomassetti","year":"1998","journal-title":"Am J Gastroenterol"},{"key":"2019041122111949200_R435","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1200\/JCO.1999.17.4.1111","article-title":"Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms.","volume":"17","author":"Wymenga","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R436","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/00000421-200008000-00020","article-title":"Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.","volume":"23","author":"Ricci","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"2019041122111949200_R437","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<770::AID-CNCR6>3.0.CO;2-0","article-title":"Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.","volume":"88","author":"O\u2019Toole","year":"2000","journal-title":"Cancer"},{"key":"2019041122111949200_R438","doi-asserted-by":"crossref","first-page":"3276","DOI":"10.1111\/j.1572-0241.2000.03210.x","article-title":"The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors.","volume":"95","author":"Ducreux","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"2019041122111949200_R439","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1200\/JCO.1999.17.2.600","article-title":"Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.","volume":"17","author":"Rubin","year":"1999","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R440","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1023\/A:1008383132024","article-title":"Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.","volume":"11","author":"Ricci","year":"2000","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R441","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2036.2003.01420.x","article-title":"Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience.","volume":"17","author":"Garland","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"2019041122111949200_R442","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1056\/NEJM198609113151102","article-title":"Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue.","volume":"315","author":"Kvols","year":"1986","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R443","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S0889-8529(18)30142-7","article-title":"The use of chemotherapy in the management of neuroendocrine tumors.","volume":"22","author":"Oberg","year":"1993","journal-title":"Endocrinol Metab Clin North Am"},{"key":"2019041122111949200_R444","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1159\/000201396","article-title":"Somatostatin receptor imaging: predictive and prognostic considerations.","volume":"57(Suppl 1)","author":"Anthony","year":"1996","journal-title":"Digestion"},{"key":"2019041122111949200_R445","doi-asserted-by":"crossref","first-page":"I36","DOI":"10.1161\/hc37t1.094898","article-title":"Surgical management of left-sided carcinoid heart disease.","volume":"104","author":"Connolly","year":"2001","journal-title":"Circulation"},{"key":"2019041122111949200_R446","doi-asserted-by":"crossref","first-page":"I51","DOI":"10.1161\/01.cir.0000032884.55215.87","article-title":"Carcinoid heart disease: impact of pulmonary valve replacement in right ventricular function and remodeling.","volume":"106","author":"Connolly","year":"2002","journal-title":"Circulation"},{"key":"2019041122111949200_R447","first-page":"834","article-title":"Somatostatin analogue (SMS 201\u2013995) in patients with gastrinomas.","volume":"104","author":"Vinik","year":"1988","journal-title":"Surgery"},{"key":"2019041122111949200_R448","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1136\/gut.42.6.792","article-title":"Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours.","volume":"42","author":"Angeletti","year":"1998","journal-title":"Gut"},{"key":"2019041122111949200_R449","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000201402","article-title":"The use of new somatostatin analogues, lanreotide and octastatin, in neuroendocrine gastro-intestinal tumours.","volume":"57(Suppl 1)","author":"Eriksson","year":"1996","journal-title":"Digestion"},{"key":"2019041122111949200_R450","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S1010-7940(02)00055-6","article-title":"Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.","volume":"21","author":"Filosso","year":"2002","journal-title":"Eur J Cardiothorac Surg"},{"key":"2019041122111949200_R451","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/j.1365-2265.1989.tb00436.x","article-title":"Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995).","volume":"30","author":"Wynick","year":"1989","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R452","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1210\/er.2000-0001","article-title":"The pathophysiological consequences of somatostatin receptor internalization and resistance.","volume":"24","author":"Hofland","year":"2003","journal-title":"Endocr Rev"},{"key":"2019041122111949200_R453","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1023\/A:1008398431246","article-title":"Long-term octreotide treatment of metastatic carcinoid tumor.","volume":"11","author":"Corleto","year":"2000","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R454","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/(SICI)1097-0142(19970215)79:4<830::AID-CNCR20>3.0.CO;2-#","article-title":"Incidence and morbidity of cholelithiasis in patients receiving chronic octreotide for metastatic carcinoid and malignant islet cell tumors.","volume":"79","author":"Trendle","year":"1997","journal-title":"Cancer"},{"key":"2019041122111949200_R455","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000055311","article-title":"Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.","volume":"60","author":"Raderer","year":"2001","journal-title":"Oncology"},{"key":"2019041122111949200_R456","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1093\/annonc\/12.suppl_2.S105","article-title":"The clinical management of neuroendocrine tumors with long-acting repeatable (LAR) octreotide: comparison with standard subcutaneous octreotide therapy.","volume":"12(Suppl 2)","author":"Dogliotti","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R457","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1530\/eje.0.1460701","article-title":"New somatostatin analogs: will they fulfil old promises?","volume":"146","author":"Lamberts","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2019041122111949200_R458","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1530\/eje.0.1460707","article-title":"SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.","volume":"146","author":"Bruns","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"2019041122111949200_R459","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endo.141.1.7259","article-title":"Intracellular dynamics of sst5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis.","volume":"141","author":"Stroh","year":"2000","journal-title":"Endocrinology"},{"key":"2019041122111949200_R460","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1210\/en.2002-220219","article-title":"SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone\/insulin-like growth factor-I axis in rats, primates, and dogs.","volume":"143","author":"Weckbecker","year":"2002","journal-title":"Endocrinology"},{"key":"2019041122111949200_R461","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000051862","article-title":"Interferon in the management of neuroendocrine GEP-tumors: a review.","volume":"62(Suppl 1)","author":"Oberg","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R462","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1600-0609.1997.tb00965.x","article-title":"How does interferon exert its cell growth inhibitory effect?","volume":"59","author":"Grander","year":"1997","journal-title":"Eur J Haematol"},{"key":"2019041122111949200_R463","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2141.1991.tb08125.x","article-title":"The role of interferons in the management of carcinoid tumours.","volume":"79(Suppl 1)","author":"Oberg","year":"1991","journal-title":"Br J Haematol"},{"key":"2019041122111949200_R464","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/02841869309083913","article-title":"An update of the medical treatment of malignant endocrine pancreatic tumors.","volume":"32","author":"Eriksson","year":"1993","journal-title":"Acta Oncol"},{"key":"2019041122111949200_R465","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1200\/JCO.1989.7.7.865","article-title":"Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon.","volume":"7","author":"Moertel","year":"1989","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R466","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3109\/00365528909089215","article-title":"Treatment of malignant metastatic midgut carcinoid tumours with recombinant human \u03b12b interferon with or without prior hepatic artery embolization.","volume":"24","author":"Hanssen","year":"1989","journal-title":"Scand J Gastroenterol"},{"key":"2019041122111949200_R467","first-page":"305","article-title":"Treatment of metastatic carcinoid tumors by recombinant human interferon-\u03b1. Results from a phase II study.","volume":"116","author":"Bartsch","year":"1990","journal-title":"J Cancer Res Clin Oncol"},{"key":"2019041122111949200_R468","doi-asserted-by":"crossref","first-page":"789","DOI":"10.3109\/00365529509096329","article-title":"Interferon-\u03b1 2b, with or without prior hepatic artery embolization: clinical response and survival in mid-gut carcinoid patients. The Norwegian carcinoid study.","volume":"30","author":"Jacobsen","year":"1995","journal-title":"Scand J Gastroenterol"},{"key":"2019041122111949200_R469","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1016\/0959-8049(92)90061-6","article-title":"Treatment of metastatic carcinoid tumour with recombinant interferon \u03b1.","volume":"28A","author":"Joensuu","year":"1992","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R470","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1002\/1097-0142(19931115)72:10<3099::AID-CNCR2820721035>3.0.CO;2-4","article-title":"Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-\u03b1-2a. A study by the Italian Trials in Medical Oncology Group.","volume":"72","author":"Bajetta","year":"1993","journal-title":"Cancer"},{"key":"2019041122111949200_R471","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1749-6632.1994.tb17297.x","article-title":"The clinical use of interferons in the management of neuroendocrine gastroenteropancreatic tumors.","volume":"733","author":"Oberg","year":"1994","journal-title":"Ann NY Acad Sci"},{"key":"2019041122111949200_R472","first-page":"3","article-title":"State of the art and future prospects in the management of neuroendocrine tumors.","volume":"44","author":"Oberg","year":"2000","journal-title":"Q J Nucl Med"},{"key":"2019041122111949200_R473","first-page":"1381","article-title":"Combination therapy with octreotide and \u03b1-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.","volume":"94","author":"Frank","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"2019041122111949200_R474","doi-asserted-by":"crossref","first-page":"2689","DOI":"10.1200\/JCO.2003.12.142","article-title":"Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon \u03b1, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors\u2013the International Lanreotide and Interferon Alfa Study Group.","volume":"21","author":"Faiss","year":"2003","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R475","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1093\/oxfordjournals.annonc.a010551","article-title":"A pilot study of combination therapy with interferon-\u03b1-2a and 5-fluorouracil in metastatic carcinoid and malignant endocrine pancreatic tumours.","volume":"7","author":"Hughes","year":"1996","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R476","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3109\/02841869309083920","article-title":"Salvage treatment after r-interferon \u03b1-2a in advanced neuroendocrine tumors.","volume":"32","author":"Zilembo","year":"1993","journal-title":"Acta Oncol"},{"key":"2019041122111949200_R477","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0936-6555(05)80494-7","article-title":"Intralesional interferon for the treatment of metastatic carcinoid tumours.","volume":"10","author":"Schneider","year":"1998","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2019041122111949200_R478","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/1097-0142(19910201)67:3<547::AID-CNCR2820670302>3.0.CO;2-J","article-title":"Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested?","volume":"67","author":"Valimaki","year":"1991","journal-title":"Cancer"},{"key":"2019041122111949200_R479","first-page":"2133","article-title":"Double modulation of 5-fluorouracil with interferon \u03b1-2a and high-dose leucovorin in advanced neuroendocrine tumours.","volume":"34","author":"Papamichael","year":"1998","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R480","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1023\/A:1012569909313","article-title":"Experience in treatment of metastatic pulmonary carcinoid tumors.","volume":"12","author":"Granberg","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R481","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/978-3-642-59587-5_4","article-title":"New molecular aspects in the diagnosis and therapy of neuroendocrine tumors of the gastroenteropancreatic system.","volume":"153","author":"Pape","year":"2000","journal-title":"Recent Results Cancer Res"},{"key":"2019041122111949200_R482","doi-asserted-by":"crossref","first-page":"178","DOI":"10.7326\/0003-4819-115-3-178","article-title":"Autoimmunity after \u03b1-interferon therapy for malignant carcinoid tumors.","volume":"115","author":"Ronnblom","year":"1991","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R483","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1023\/A:1008314804492","article-title":"The interferon-\u03b1 regulation of interferon regulatory factor 1 (IRF-1) and IRF-2 has therapeutic implications in carcinoid tumors.","volume":"11","author":"Zhou","year":"2000","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R484","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1530\/acta.0.1260184","article-title":"Dramatic response of a metastatic carcinoid tumour to a combination of interferon and octreotide.","volume":"126","author":"Joensuu","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"2019041122111949200_R485","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/0959-8049(92)90060-F","article-title":"Octreotide and interferon \u03b1: a new combination for the treatment of malignant carcinoid tumours.","volume":"28A","author":"Tiensuu Janson","year":"1992","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R486","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1385\/MO:19:1:35","article-title":"Treatment of malignant endocrine pancreatic tumors with a combination of \u03b1-interferon and somatostatin analogs.","volume":"19","author":"Fjallskog","year":"2002","journal-title":"Med Oncol"},{"key":"2019041122111949200_R487","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/003655202753416957","article-title":"Management of enterochromaffin-like gastric carcinoid tumour metastasized to the liver.","volume":"37","author":"Kouraklis","year":"2002","journal-title":"Scand J Gastroenterol"},{"key":"2019041122111949200_R488","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000051859","article-title":"Chemotherapy in the treatment of neuroendocrine malignant tumors.","volume":"62(Suppl 1)","author":"Rougier","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R489","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1002\/1097-0142(19900501)65:9<1883::AID-CNCR2820650902>3.0.CO;2-3","article-title":"Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors.","volume":"65","author":"Eriksson","year":"1990","journal-title":"Cancer"},{"key":"2019041122111949200_R490","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0305-7372(94)90016-7","article-title":"Treatment of neuroendocrine tumors.","volume":"20","author":"Oberg","year":"1994","journal-title":"Cancer Treat Rev"},{"key":"2019041122111949200_R491","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1056\/NEJM199202203260804","article-title":"Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.","volume":"326","author":"Moertel","year":"1992","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R492","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1200\/JCO.1984.2.11.1255","article-title":"Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor.","volume":"2","author":"Engstrom","year":"1984","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R493","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198011203032101","article-title":"Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma.","volume":"303","author":"Moertel","year":"1980","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R494","doi-asserted-by":"crossref","first-page":"108","DOI":"10.7326\/0003-4819-79-1-108","article-title":"Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients.","volume":"79","author":"Broder","year":"1973","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R495","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1200\/JCO.1992.10.12.1914","article-title":"Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study.","volume":"10","author":"Bukowski","year":"1992","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R496","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/(SICI)1097-0142(19980715)83:2<372::AID-CNCR23>3.0.CO;2-P","article-title":"5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors.","volume":"83","author":"Bajetta","year":"1998","journal-title":"Cancer"},{"key":"2019041122111949200_R497","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/00000421-199802000-00008","article-title":"Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma.","volume":"21","author":"Rivera","year":"1998","journal-title":"Am J Clin Oncol"},{"key":"2019041122111949200_R498","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2265.2002.01589.x","article-title":"Treatment of advanced neuroendocrine tumours using combination chemotherapy with lomustine and 5-fluorouracil.","volume":"57","author":"Kaltsas","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R499","first-page":"327","article-title":"Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome.","volume":"2","author":"Moertel","year":"1979","journal-title":"Cancer Clin Trials"},{"key":"2019041122111949200_R500","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/02841868709113712","article-title":"Cytotoxic treatment in patients with malignant carcinoid tumors. Response to streptozocin\u2013alone or in combination with 5-FU.","volume":"26","author":"Oberg","year":"1987","journal-title":"Acta Oncol"},{"key":"2019041122111949200_R501","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1002\/1097-0142(19871215)60:12<2891::AID-CNCR2820601207>3.0.CO;2-6","article-title":"A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study.","volume":"60","author":"Bukowski","year":"1987","journal-title":"Cancer"},{"key":"2019041122111949200_R502","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/0277-5379(91)90014-5","article-title":"Metastatic carcinoid and islet cell tumours of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouracil, doxorubicin and cisplatin.","volume":"27","author":"Rougier","year":"1991","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R503","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2265.1990.tb00872.x","article-title":"Successful treatment by chemotherapy for acromegaly associated with ectopic growth hormone releasing hormone secretion from a carcinoid tumour.","volume":"32","author":"Harris","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0936-6555(97)80132-X","article-title":"Chemotherapy for neuroendocrine tumors: the Beatson Oncology Centre experience.","volume":"9","author":"Hatton","year":"1997","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2019041122111949200_R505","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/1097-0142(20010901)92:5<1101::AID-CNCR1426>3.0.CO;2-V","article-title":"Treatment with cisplatin and etoposide in patients with neuroendocrine tumors.","volume":"92","author":"Fjallskog","year":"2001","journal-title":"Cancer"},{"key":"2019041122111949200_R506","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1093\/annonc\/10.suppl_4.S185","article-title":"Pancreatic endocrine tumours, immunotherapy and gene therapy: chemotherapy and interferon therapy of endocrine tumours.","volume":"10(Suppl 4)","author":"Veenhof","year":"1999","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R507","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms.","volume":"68","author":"Moertel","year":"1991","journal-title":"Cancer"},{"key":"2019041122111949200_R508","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1002\/1097-0142(19830301)51:5<882::AID-CNCR2820510522>3.0.CO;2-8","article-title":"Carcinoids: the association of histologic growth pattern and survival.","volume":"51","author":"Johnson","year":"1983","journal-title":"Cancer"},{"key":"2019041122111949200_R509","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.bjc.6690325","article-title":"Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin.","volume":"81","author":"Mitry","year":"1999","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R510","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/1097-0142(20010415)91:8<1543::AID-CNCR1163>3.0.CO;2-N","article-title":"A phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors.","volume":"91","author":"Ansell","year":"2001","journal-title":"Cancer"},{"key":"2019041122111949200_R511","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1002\/cncr.10592","article-title":"7-Hydroxytryptophan, a novel, specific, cytotoxic agent for carcinoids and other serotonin-producing tumors.","volume":"94","author":"Walther","year":"2002","journal-title":"Cancer"},{"key":"2019041122111949200_R512","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1073\/pnas.95.4.1794","article-title":"Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin.","volume":"95","author":"Nagy","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019041122111949200_R513","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/eje.0.1410001","article-title":"Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors.","volume":"141","author":"Schally","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"2019041122111949200_R514","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1038\/sj.bjc.6601346","article-title":"A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).","volume":"89","author":"Hopfner","year":"2003","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R515","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000051860","article-title":"Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors.","volume":"62(Suppl 1)","author":"Ruszniewski","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R516","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1072-7515(98)00099-4","article-title":"Isolated liver metastases from neuroendocrine tumors: does resection prolong survival?","volume":"187","author":"Chen","year":"1998","journal-title":"J Am Coll Surg"},{"key":"2019041122111949200_R517","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J Am Coll Surg"},{"key":"2019041122111949200_R518","first-page":"673","article-title":"Liver metastases of digestive endocrine tumours: natural history and response to medical treatment.","volume":"8","author":"Skinazi","year":"1996","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2019041122111949200_R519","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0039-6060(97)90221-X","article-title":"Laparoscopic thermal ablation of hepatic neuroendocrine tumor metastases.","volume":"122","author":"Siperstein","year":"1997","journal-title":"Surgery"},{"key":"2019041122111949200_R520","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1007\/s00268-002-6663-3","article-title":"Radiofrequency tissue ablation using cooled tip for liver metastases of endocrine tumors.","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"key":"2019041122111949200_R521","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S0002-9610(99)80107-X","article-title":"Hepatic resection for metastatic neuroendocrine carcinomas.","volume":"169","author":"Que","year":"1995","journal-title":"Am J Surg"},{"key":"2019041122111949200_R522","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/(SICI)1096-9098(199808)68:4<242::AID-JSO7>3.0.CO;2-4","article-title":"Cryosurgical ablation of unresectable hepatic metastases.","volume":"68","author":"Dale","year":"1998","journal-title":"J Surg Oncol"},{"key":"2019041122111949200_R523","first-page":"1637","article-title":"Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up.","volume":"35","author":"Andrews","year":"1994","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R524","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1749-6632.1994.tb17298.x","article-title":"Neuroendocrine tumors metastatic to the liver. Vascular occlusion therapy.","volume":"733","author":"Ajani","year":"1994","journal-title":"Ann NY Acad Sci"},{"key":"2019041122111949200_R525","doi-asserted-by":"crossref","first-page":"302","DOI":"10.7326\/0003-4819-120-4-199402150-00008","article-title":"The management of patients with advanced carcinoid tumors and islet cell carcinomas.","volume":"120","author":"Moertel","year":"1994","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R526","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1148\/radiology.191.1.8134569","article-title":"Hemodynamic changes after transcatheter arterial embolization of hepatocellular carcinomas.","volume":"191","author":"Taourel","year":"1994","journal-title":"Radiology"},{"key":"2019041122111949200_R527","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/0002-9610(92)90392-5","article-title":"Effective palliative treatment of metastatic carcinoid tumors with intra-arterial chemotherapy\/chemoembolization combined with octreotide acetate.","volume":"163","author":"Hajarizadeh","year":"1992","journal-title":"Am J Surg"},{"key":"2019041122111949200_R528","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1148\/radiology.189.2.7692465","article-title":"Transcatheter chemoembolization of progressive carcinoid liver metastasis.","volume":"189","author":"Therasse","year":"1993","journal-title":"Radiology"},{"key":"2019041122111949200_R529","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0002-9610(99)80210-4","article-title":"Treatment of metastatic carcinoid tumors using multimodality therapy of octreotide acetate, intra-arterial chemotherapy, and hepatic arterial chemoembolization.","volume":"169","author":"Diaco","year":"1995","journal-title":"Am J Surg"},{"key":"2019041122111949200_R530","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/1097-0142(19930715)72:2<375::AID-CNCR2820720211>3.0.CO;2-D","article-title":"Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liver.","volume":"72","author":"Mavligit","year":"1993","journal-title":"Cancer"},{"key":"2019041122111949200_R531","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000201208","article-title":"Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.","volume":"55(Suppl 3)","author":"Clouse","year":"1994","journal-title":"Digestion"},{"key":"2019041122111949200_R532","first-page":"1111","article-title":"Hepatic arterial chemoembolization for metastatic neuroendocrine tumors.","volume":"116","author":"Perry","year":"1994","journal-title":"Surgery"},{"key":"2019041122111949200_R533","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0002-9610(98)00042-7","article-title":"Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors.","volume":"175","author":"Drougas","year":"1998","journal-title":"Am J Surg"},{"key":"2019041122111949200_R534","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000074522","article-title":"Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors: a retrospective single-center analysis.","volume":"68","author":"Kress","year":"2003","journal-title":"Digestion"},{"key":"2019041122111949200_R535","first-page":"73","article-title":"Radiotherapy for unresectable endocrine pancreatic carcinomas.","volume":"18","author":"Tennvall","year":"1992","journal-title":"Eur J Surg Oncol"},{"key":"2019041122111949200_R536","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1002\/1097-0142(19940301)73:5<1346::AID-CNCR2820730507>3.0.CO;2-C","article-title":"Clinical and biochemical effects in vivo of monoclonal antitumor antibody in Verner-Morrison\u2019s syndrome.","volume":"73","author":"Juhlin","year":"1994","journal-title":"Cancer"},{"key":"2019041122111949200_R537","first-page":"77","article-title":"Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.","volume":"44","author":"Castellani","year":"2000","journal-title":"Q J Nucl Med"},{"key":"2019041122111949200_R538","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1097\/00003072-200203000-00007","article-title":"I-123 MIBG imaging and intraoperative localization of metastatic pheochromocytoma: a case report.","volume":"27","author":"Buhl","year":"2002","journal-title":"Clin Nucl Med"},{"key":"2019041122111949200_R539","first-page":"269","article-title":"Radiopharmaceutical therapy of malignant pheochromocytoma with [131I]metaiodobenzylguanidine: results from ten years of experience.","volume":"35","author":"Shapiro","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R540","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1097\/00006231-199310000-00004","article-title":"Treatment of malignant phaeochromocytoma, paraganglioma and carcinoid tumours with 131I-metaiodobenzylguanidine.","volume":"14","author":"Bomanji","year":"1993","journal-title":"Nucl Med Commun"},{"key":"2019041122111949200_R541","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1200\/JCO.1996.14.6.1829","article-title":"Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.","volume":"14","author":"Taal","year":"1996","journal-title":"J Clin Oncol"},{"key":"2019041122111949200_R542","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1023\/A:1011160913619","article-title":"The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study.","volume":"12","author":"Waldherr","year":"2001","journal-title":"Ann Oncol"},{"key":"2019041122111949200_R543","first-page":"1263","article-title":"[Yttrium 90 DOTATOC: a new somatostatin analog for cancer therapy of neuroendocrine tumors].","volume":"88","author":"Otte","year":"1999","journal-title":"Schweiz Rundsch Med Prax"},{"key":"2019041122111949200_R544","first-page":"685","article-title":"[(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas.","volume":"86","author":"Harst","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R545","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF00182305","article-title":"Predictors of toxicity in treating patients with neuroblastoma by radiolabeled metaiodobenzylguanidine.","volume":"21","author":"Sisson","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R546","first-page":"280","article-title":"Radiolabelled metaiodobenzylguanidine targeted radiotherapy for malignant phaeochromocytoma.","volume":"35","author":"Lewington","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R547","first-page":"1024","article-title":"Acute liver necrosis induced by iodine-131-MIBG in the treatment of metastatic carcinoid tumors.","volume":"38","author":"Bongers","year":"1997","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R548","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0936-6555(02)00273-X","article-title":"Treatment of neuroendocrine tumours in adults with 131I-MIBG therapy.","volume":"15","author":"Bomanji","year":"2003","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2019041122111949200_R549","first-page":"1519","article-title":"Systemic radionuclide therapy using indium-111-DTPA-D-Phe1-octreotide in midgut carcinoid syndrome.","volume":"37","author":"Fjalling","year":"1996","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R550","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/snuc.2002.31769","article-title":"Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies.","volume":"32","author":"Anthony","year":"2002","journal-title":"Semin Nucl Med"},{"key":"2019041122111949200_R551","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s002590100502","article-title":"Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.","volume":"28","author":"Breeman","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R552","first-page":"1","article-title":"Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors.","volume":"44","author":"Buscombe","year":"2003","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R553","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1053\/snuc.2002.31027","article-title":"Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings.","volume":"32","author":"Jong","year":"2002","journal-title":"Semin Nucl Med"},{"key":"2019041122111949200_R554","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000051858","article-title":"OctreoTher: ongoing early clinical development of a somatostatin-receptor-targeted radionuclide antineoplastic therapy.","volume":"62(Suppl 1)","author":"Smith","year":"2000","journal-title":"Digestion"},{"key":"2019041122111949200_R555","first-page":"368","article-title":"Yttrium-90 and indium-111 labelling, receptor binding and biodistribution of [DOTA0,d-Phe1,Tyr3]octreotide, a promising somatostatin analogue for radionuclide therapy.","volume":"24","author":"Jong","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R556","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1007\/s002590100490","article-title":"Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide.","volume":"28","author":"Paganelli","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R557","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results.","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R558","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1053\/snuc.2002.31565","article-title":"In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial.","volume":"32","author":"Virgolini","year":"2002","journal-title":"Semin Nucl Med"},{"key":"2019041122111949200_R559","first-page":"2090","article-title":"Response to treatment with yttrium 90-DOTA-lanreotide of a patient with metastatic gastrinoma.","volume":"39","author":"Leimer","year":"1998","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R560","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1007\/s002590100574","article-title":"[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.","volume":"28","author":"Kwekkeboom","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"2019041122111949200_R561","first-page":"617","article-title":"New advances in peptide receptor radionuclide therapy.","volume":"43","author":"Jong","year":"2002","journal-title":"J Nucl Med"},{"key":"2019041122111949200_R562","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/1097-0215(20000820)90:4<186::AID-IJC2>3.0.CO;2-P","article-title":"Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumour imaging and radionuclide therapy.","volume":"90","author":"Hagen","year":"2000","journal-title":"Int J Cancer"},{"key":"2019041122111949200_R563","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000049168","article-title":"Somatostatin analogs in oncology: a look to the future.","volume":"47(Suppl 2)","author":"Jenkins","year":"2001","journal-title":"Chemotherapy"},{"key":"2019041122111949200_R564","doi-asserted-by":"crossref","first-page":"477","DOI":"10.7326\/0003-4819-99-4-477","article-title":"Pheochromocytoma and prazosin.","volume":"99","author":"Nicholson Jr","year":"1983","journal-title":"Ann Intern Med"},{"key":"2019041122111949200_R565","first-page":"1149","article-title":"Exclusive use of calcium channel blockers in preoperative and intraoperative control of pheochromocytomas: hemodynamics and free catecholamine assays in ten consecutive patients.","volume":"106","author":"Proye","year":"1989","journal-title":"Surgery"},{"key":"2019041122111949200_R566","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/S0140-6736(68)91579-1","article-title":"\u03b1-methyl-p-tyrosine in the management of phaeochromocytoma.","volume":"2","author":"Jones","year":"1968","journal-title":"Lancet"},{"key":"2019041122111949200_R567","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJM198405103101917","article-title":"Reduction in the size of a pheochromocytoma pulmonary metastasis by metyrosine therapy.","volume":"310","author":"Serri","year":"1984","journal-title":"N Engl J Med"},{"key":"2019041122111949200_R568","doi-asserted-by":"crossref","first-page":"940","DOI":"10.2169\/internalmedicine.37.940","article-title":"Cardiac malignant pheochromocytoma with bone metastases.","volume":"37","author":"Arai","year":"1998","journal-title":"Intern Med"},{"key":"2019041122111949200_R569","first-page":"295","article-title":"Three cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine, and dacarbazine combination chemotherapy and \u03b1-methyl-p-tyrosine to control hypercatecholaminemia.","volume":"49","author":"Tada","year":"1998","journal-title":"Horm Res"},{"key":"2019041122111949200_R570","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1046\/j.1365-2265.1997.d01-1738.x","article-title":"Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma.","volume":"46","author":"Kopf","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R571","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.1365-2265.1995.tb01877.x","article-title":"Short-term effects of octreotide on blood pressure and plasma catecholamines and neuropeptide Y levels in patients with phaeochromocytoma: a placebo-controlled trial.","volume":"42","author":"Plouin","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R572","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000183786","article-title":"Effect of octreotide on catecholamine plasma levels in patients with chromaffin cell tumors.","volume":"40","author":"Invitti","year":"1993","journal-title":"Horm Res"},{"key":"2019041122111949200_R573","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1046\/j.1365-2265.2002.01658.x","article-title":"Effects of slow-release octreotide on urinary metanephrine excretion and plasma chromogranin A and catecholamine levels in patients with malignant or recurrent phaeochromocytoma.","volume":"57","author":"Lamarre-Cliche","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R574","first-page":"46","article-title":"Control of catecholamine release and blood pressure with octreotide in a patient with pheochromocytoma: a case report with in vitro studies.","volume":"53","author":"Koriyama","year":"2000","journal-title":"Horm Res"},{"key":"2019041122111949200_R575","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/BF01798547","article-title":"[Therapy of a malignant sympathetic paraganglioma of the organ of Zuckerkandl\u2013a case report].","volume":"69","author":"Schuppert","year":"1991","journal-title":"Klin Wochenschr"},{"key":"2019041122111949200_R576","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/BF03345808","article-title":"Malignant pheochromocytoma: a series of 14 cases observed between 1966 and 1990.","volume":"15","author":"Mornex","year":"1992","journal-title":"J Endocrinol Invest"},{"key":"2019041122111949200_R577","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2169\/internalmedicine.38.349","article-title":"Malignant pheochromocytoma with multiple hepatic metastases treated by chemotherapy and transcatheter arterial embolization.","volume":"38","author":"Takahashi","year":"1999","journal-title":"Intern Med"},{"key":"2019041122111949200_R578","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2169\/internalmedicine.38.433","article-title":"Palliative chemotherapy for malignant pheochromocytoma: symptomatic palliation of two cases.","volume":"38","author":"Iwabuchi","year":"1999","journal-title":"Intern Med"},{"key":"2019041122111949200_R579","doi-asserted-by":"crossref","first-page":"I18","DOI":"10.1161\/01.HYP.7.3_Pt_2.I18","article-title":"Treatment of malignant pheochromocytoma with combination chemotherapy","volume":"7","author":"Keiser","year":"1985","journal-title":"Hypertension"},{"key":"2019041122111949200_R580","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/1097-0142(19880815)62:4<686::AID-CNCR2820620407>3.0.CO;2-7","article-title":"High-voltage irradiation and combination chemotherapy for malignant pheochromocytoma.","volume":"62","author":"Siddiqui","year":"1988","journal-title":"Cancer"},{"key":"2019041122111949200_R581","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/BF03345810","article-title":"High incidence of malignant pheochromocytoma in a surgical unit. 26 cases out of 100 patients operated from 1971 to 1991.","volume":"15","author":"Proye","year":"1992","journal-title":"J Endocrinol Invest"},{"key":"2019041122111949200_R582","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/0959-8049(92)90173-Y","article-title":"Palliation of malignant phaeochromocytoma with combination chemotherapy","volume":"28A","author":"Senan","year":"1992","journal-title":"Eur J Cancer"},{"key":"2019041122111949200_R583","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1507\/endocrj.41.155","article-title":"A case of Sipple\u2019s syndrome with malignant pheochromocytoma treated with 131I-metaiodobenzyl guanidine and a combined chemotherapy with cyclophosphamide, vincristine and dacarbazine.","volume":"41","author":"Sasaki","year":"1994","journal-title":"Endocr J"},{"key":"2019041122111949200_R584","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/mpo.2950220607","article-title":"Hypertensive crises induced by treatment of malignant pheochromocytoma with a combination of cyclophosphamide, vincristine, and dacarbazine.","volume":"22","author":"Wu","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"2019041122111949200_R585","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1507\/endocrj.43.279","article-title":"Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy.","volume":"43","author":"Noshiro","year":"1996","journal-title":"Endocr J"},{"key":"2019041122111949200_R586","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0022-3468(94)90799-4","article-title":"Pediatric malignant pheochromocytoma.","volume":"29","author":"Ein","year":"1994","journal-title":"J Pediatr Surg"},{"key":"2019041122111949200_R587","first-page":"801","article-title":"Clinical experience with malignant pheochromocytomas.","volume":"154","author":"Scott Jr","year":"1982","journal-title":"Surg Gynecol Obstet"},{"key":"2019041122111949200_R588","first-page":"543","article-title":"Treatment of metastatic para-aortic paraganglioma by surgery, radiotherapy and I-131 mIBG.","volume":"17","author":"Ball","year":"1991","journal-title":"Eur J Surg Oncol"},{"key":"2019041122111949200_R589","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/00000421-200202000-00008","article-title":"Radiation treatment of recurrent pheochromocytoma of the bladder: case report and review of literature.","volume":"25","author":"Naguib","year":"2002","journal-title":"Am J Clin Oncol"},{"key":"2019041122111949200_R590","first-page":"327","article-title":"The role of [131I]metaiodobenzylguanidine in the treatment of medullary thyroid carcinoma: results in five cases.","volume":"35","author":"Troncone","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R591","first-page":"288","article-title":"[131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma.","volume":"35","author":"Lumbroso","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R592","first-page":"292","article-title":"Therapy of pheochromocytoma with [131I]metaiodobenzylguanidine.","volume":"35","author":"Fischer","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R593","first-page":"277","article-title":"Results of [131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma.","volume":"35","author":"Bestagno","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R594","first-page":"300","article-title":"Preliminary results of [131]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma.","volume":"35","author":"Colombo","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R595","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03165029","article-title":"Radionuclide therapy of malignant pheochromocytoma with 131I-MIBG.","volume":"8","author":"Nakabeppu","year":"1994","journal-title":"Ann Nucl Med"},{"key":"2019041122111949200_R596","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF03165018","article-title":"131I-metaiodobenzylguanidine therapy for malignant pheochromocytoma.","volume":"8","author":"Sakahara","year":"1994","journal-title":"Ann Nucl Med"},{"key":"2019041122111949200_R597","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/01.TEN.0000084154.02341.ad","article-title":"Treatment of metastatic pheochromocytoma and paraganglioma with 131I-meta-iodobenzylguanidine (MIBG).","volume":"13","author":"Kaltsas","year":"2003","journal-title":"The Endocrinologist"},{"key":"2019041122111949200_R598","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/snuc\/2002.31025","article-title":"Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.","volume":"32","author":"Valkema","year":"2002","journal-title":"Semin Nucl Med"},{"key":"2019041122111949200_R599","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2169\/internalmedicine.32.789","article-title":"Malignant pheochromocytoma with hepatic metastasis diagnosed 20 years after resection of the primary adrenal lesion.","volume":"32","author":"Tanaka","year":"1993","journal-title":"Intern Med"},{"key":"2019041122111949200_R600","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/jnci\/93.8.648","article-title":"Radiofrequency ablation: a novel approach for treatment of metastatic pheochromocytoma.","volume":"93","author":"Pacak","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"2019041122111949200_R601","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/00000421-199908000-00008","article-title":"Treatment of malignant pheochromocytomas with 131-I metaiodobenzylguanidine and chemotherapy.","volume":"22","author":"Sisson","year":"1999","journal-title":"Am J Clin Oncol"},{"key":"2019041122111949200_R602","first-page":"361","article-title":"Management of malignant phaeochromocytoma: a retrospective review of the use of MIBG and chemotherapy in the West Midlands.","volume":"13","author":"Hartley","year":"2001","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2019041122111949200_R603","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1097\/00042737-199910000-00014","article-title":"Long-term palliation in metastatic carcinoid tumours with various applications of meta-iodobenzylguanidin (MIBG): pharmacological MIBG, 131I-labelled MIBG and the combination.","volume":"11","author":"Zuetenhorst","year":"1999","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2019041122111949200_R604","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1148\/123.3.745","article-title":"The role of radiation therapy in medullary carcinoma of the thyroid.","volume":"123","author":"Steinfeld","year":"1977","journal-title":"Radiology"},{"key":"2019041122111949200_R605","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/bjc.1995.73","article-title":"Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d\u2019Etude des Tumeurs a Calcitonine (GETC).","volume":"71","author":"Schlumberger","year":"1995","journal-title":"Br J Cancer"},{"key":"2019041122111949200_R606","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1210\/jcem-57-1-124","article-title":"Radioactive iodine in the treatment of medullary carcinoma of the thyroid.","volume":"57","author":"Saad","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R607","first-page":"334","article-title":"Role of [131I]metaiodobenzylguanidine therapy in medullary thyroid carcinoma.","volume":"35","author":"Hoefnagel","year":"1991","journal-title":"J Nucl Biol Med"},{"key":"2019041122111949200_R608","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2265.1990.tb00490.x","article-title":"Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide.","volume":"33","author":"Mahler","year":"1990","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R609","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/j.1365-2265.1992.tb00955.x","article-title":"Results of long-term continuous subcutaneous octreotide administration in 14 patients with medullary thyroid carcinoma.","volume":"36","author":"Modigliani","year":"1992","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2019041122111949200_R610","first-page":"983","article-title":"Slow release lanreotide in combination with interferon-\u03b12b in the treatment of symptomatic advanced medullary thyroid carcinoma.","volume":"85","author":"Vitale","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R611","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1002\/(SICI)1097-0142(19960901)78:5<1114::AID-CNCR23>3.0.CO;2-4","article-title":"Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon \u03b1-2b and octreotide.","volume":"78","author":"Lupoli","year":"1996","journal-title":"Cancer"},{"key":"2019041122111949200_R612","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1002\/1097-0142(19881101)62:9<1899::AID-CNCR2820620905>3.0.CO;2-C","article-title":"Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil.","volume":"62","author":"Petursson","year":"1988","journal-title":"Cancer"},{"key":"2019041122111949200_R613","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0002-9343(97)00024-7","article-title":"Advances and controversies in the diagnosis and management of medullary thyroid carcinoma.","volume":"103","author":"Heshmati","year":"1997","journal-title":"Am J Med"},{"key":"2019041122111949200_R614","first-page":"3190","article-title":"Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I\/II clinical trial.","volume":"5","author":"Kraeber-Bodere","year":"1999","journal-title":"Clin Cancer Res"},{"key":"2019041122111949200_R615","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1002\/(SICI)1097-0142(19990415)85:8<1828::AID-CNCR25>3.0.CO;2-H","article-title":"Phase I\/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.","volume":"85","author":"Juweid","year":"1999","journal-title":"Cancer"},{"key":"2019041122111949200_R616","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1210\/jcem.86.10.7949","article-title":"Immunotherapy for medullary thyroid carcinoma by dendritic cell vaccination.","volume":"86","author":"Schott","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R617","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1210\/jcem.87.3.8283","article-title":"Stimulation of autologous antitumor T-cell responses against medullary thyroid carcinoma using tumor lysate-pulsed dendritic cells.","volume":"87","author":"Bachleitner-Hofmann","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2019041122111949200_R618","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0030-6665(02)00136-6","article-title":"Medullary thyroid cancer.","volume":"36","author":"Clayman","year":"2003","journal-title":"Otolaryngol Clin North Am"},{"key":"2019041122111949200_R619","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s11864-003-0009-8","article-title":"Medullary thyroid carcinoma.","volume":"4","author":"Moley","year":"2003","journal-title":"Curr Treat Options Oncol"},{"key":"2019041122111949200_R620","first-page":"7284","article-title":"ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.","volume":"62","author":"Carlomagno","year":"2002","journal-title":"Cancer Res"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/edrv\/article-pdf\/25\/3\/458\/8861951\/edrv0458.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,13]],"date-time":"2024-01-13T15:36:09Z","timestamp":1705160169000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/25\/3\/458\/2355262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,1]]},"references-count":620,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,10,31]]},"published-print":{"date-parts":[[2004,6,1]]}},"URL":"https:\/\/doi.org\/10.1210\/er.2003-0014","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,1]]}}}